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Tissue engineering 
On the quest for tissue and organ replacement, the usage of donated organs represents a first 
successful step, but is connected with strong side effects, e.g. the lifelong medical suppression 
of the immune system to prevent rejection of the allograft donor material. To overcome these 
disadvantages of allografts, a major target in transplantation medicine represents the 
utilization of autograft tissue material, harvested directly from the patient as primary or stem 
cells and prepared by tissue engineering (TE) methods for the desired application [1]. The 
methods of tissue engineering are based on simulation of the regular tissue growth and trauma 
healing processes utilizing artifical cell carrier systems, which can act as some kind of 
artifical extracellular matrix, morphogens like growth factors, which have the potential to 
retain cellular phenotype, increase growth rate and increase differentiation to a specific cell 
phenotype, and pre-cultivation under specific in vitro conditions and subsequent re-
implantation.  
Since the establishment of the field in the 1990 the number of cultivated tissue types, 
applicable biomaterials, morphogens and engineering techniques have increased rapidly, as 
well as the possible field of application in vivo and in vitro. 
Articular cartilage biology 
Articular cartilage consists of a small number of chondrocytes embedded in an extracellular 
matrix (ECM). Primary function of chondrocytes is to synthesize and maintain this ECM that 
is able to withstand physical deformation and facilitates tissue function [2]. The chondrocytes, 
which compose only 5% of wet weight of articular cartilage, furthermore orchestrate a 
balance between ECM synthesis and breakdown and, thus, regulate the normal tissue 
metabolism. Articular cartilage provides outstanding mechanical properties, as it is durable 
against countless numbers of repetitive strains. This durability results from the special 
composition of ECM consisting of collagen fibers, proteoglycans and embedded water, the 
latter of which accounts for approximately three-quarter of wet weight. The cross-linked and 
interconnected collagen fibrils consist mainly of collagen type II and some minor fractions of 
collagen type IX and XI. The proteoglycans are dominated by aggrecan, a highly glycosylated 
protein. Aggrecan consists mainly of glycosaminoglycan chains, which contain chondroitin 
sulfate and keratin sulfate. The aggrecans show high affinity to hyaluronic acid, a long 
polysaccharide chain molecule. The forming of these aggrecan-hyaluronic acid aggregates is 
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stabilized by link proteins. Further minor proteoglycans can be found in cartilage, namely 
decorin, biglycan and fibromodulin, which help to stabilize the matrix [3].  
 
 
Fig. 1: Articular cartilage structure. Schematic representation of adult articular cartilage organization of matrix 
and cells into zones [4].  
 
Articular chondrocytes form a 2 to 5 mm thick, gel-like, avascular white composite matrix 
tissue. This tissue is divided in three different zones, each with different morphology and 
arrangement of type II collagen fibers. The superficial zone (Fig. 1) has more flattened 
chondrocytes and collagen fibrils aligned parallel to the surface. Subsequently the transitional 
zone which is of the largest thickness shows rounded cells and transversely to the surface 
orientated collagen fibers. In the deep zone cells and collagen fibers are arranged 
perpendicular to the cartilage surface [3]. 
The supply of articular cartilage with nutrients and further metabolite exchange relies on 
diffusion from the articular surface, because the tissue is not vascularised. So the cell 
metabolism is adapted to a low oxygen tension (between 7-10% at the surface to below 1% in 
the deep layers). As a result the energy generation comes from glycolysis and so the 
chondrocytes do not contain abundant mitochondria [2]. Even so, the cells can be remarkably 
active synthetically. The adaption to low oxygen tensions seems to be regulated by expression 
levels of several factors, e.g. hypoxia inducible factor (HIF) [5] and TGF-β [6].  
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Articular cartilage in focus of TE 
The biology and anatomy of articular cartilage is characterized by a low cell density, 
avascularity and high extracellular matrix content. It is a highly specialized tissue with only 
limited capacity for self repair. Articular cartilage undergoes degradation processes in 
response to e.g. metabolic, genetic and mechanical disorders as well as mechanical trauma [3] 
and this is often connected with constant deep pain and restriction in motion of the patients. A 
generally progressive loss and degeneration of cartilage is known as osteoarthritis (OA) and in 
most severe cases lead to joint deformities and subluxations [7, 8, 8]. The prevalence of OA 
increases with age, as more than one third of people over 45 years report joint symptoms such 
as intermitted aching up to permanent pain or occasional joint stiffness [8]. Of people over 65 
years more than 75% have OA [7]. But even young people suffer from secondary 
osteoarthritis in consequence of e.g. joint trauma from accidents. Therefore, the wide 
prevalence of articular cartilage diseases makes therapeutic treatments eligible which not only 
relieve pain but lead to a healing of the morbid cartilage tissue. Some first commercial 
products for the tissue engineering of cartilage have reached the market (Carticel ®, 
Hyalograft C ®) yielding promising results in repair of punctual defects of the articular 
cartilage surface. First studies reported from acceptable long-term results monitored by 
magnetic resonance imaging (MRI) observation with a subjective improvement rate of 
about 81% [9, 10].  
 
But most basic questions and problems for tissue engineering of cartilage still remain 
unanswered or unsolved. They need to be answered to produce a tissue that fully regenerates 
the natural zonal organization of articular cartilage, which is still not achieved even after 
several months in vivo [11]. The main points are the polymer material used for scaffolding, 
the type of cells used for TE (differentiated or progenitor), the use of suitable growth factors 
to influence cellular development and an improvement in integration of the newly formed 
tissue implants into the existing natural cartilage tissue. The usage of growth factors or other 
morphogens can be improved by controlled release devices [12, 13], which might also 
function as cell carrier matrix, e.g. smart polymeric scaffolds loaded with growth factors, or 
as a pure release device within the synovial joint [14].  
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A further problem can be seen in the limitation in the number of harvestable cells to form 
autologous TE implants. So an approach to overcome this problem consists in the prior 
proliferation of harvested cells in a 2-D culture, which commonly results in cell 
dedifferentiation rendering the cells less suitable for tissue engineering purposes [15]. 
In general, the limited capacity of self repair paired with the reduced nutrient consumption 
makes cartilage an interesting tissue material for tissue engineering [16, 17]. Furthermore, as 
a non-vascularized tissue consisting of only one cell type, articular cartilage is likely a major 
candidate to be successfully regenerated by tissue engineering methods.´ 
 
Goals of Thesis 
In this thesis three major problems in the field of tissue engineering of cartilage were focused 
on in an established bovine cartilage culture [18]. Firstly, the suitability of controlled release 
devices for long-term delivery of protein growth factors was determined. Secondly, 
morphogens were investigated with regard to their ability either to enable the redifferentiation 
of expanded chondrocytes and the concurrent generation of relevant cartilaginous constructs 
or to improve extracellular matrix composition of constructs made from primary 
chondrocytes. As a third aspect, the influence of differential oxygen partial pressure on the 
development of tissue engineered cartilage was investigated. 
 
Drug delivery systems in tissue engineering 
The method of delivery of morphogenetic effectors like growth factors to the cells draws 
increasing attention in the field of tissue engineering [12], as the emulation of natural growth 
factor production could lead to improved developing or regenerating tissues [19]. However, 
the administration and utilization of protein growth factors is limited by their short half-lives 
at in vivo application [20]. The release of protein growth factors from controlled release 
devices is further limited by a loss of bioactivity during production of the device. This loss of 
activity results from denaturation and deactivation of protein during the formulation process 
with a polymer matrix [12]. This makes protein carriers desirable, which could ensure a 
sustained release and at the same time retain the biological activity of the growth factors [21]. 
Within our research group, recently a lipid-based controlled release matrix system was 
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developed in which insulin was incorporated as model growth factor [22]. These lipid 
matrices were investigated with regard to the release of bioactive insulin in our chondrocyte 
TE cell culture (chapter 3).  
Furthermore, smart cell carriers are desirable, which combine the function of an artificial 
extracellular matrix ensuring cell attachment and the release of adequate growth factor 
concentrations at the site of action over an extended period of time. Recently, in our group the 
manufacturing of macroporous scaffolds using the newly developed lipid-templating 
technique has been demonstrated [23, 24]. These macroporous scaffolds were also loaded 
with insulin and tested in our chondrocyte TE cell culture with regard to the development of 
cartilaginous constructs (chapter 4). 
 
Morphogens for cartilage tissue engineering 
The second aim of this thesis was to investigate the effects of morphogens on the 
development of TE cartilage constructs. Growth and differentiation factor-5 (GDF-5) is 
known as a prominent growth factor in the embryonic precartilaginous mesenchymal 
condensation and in digit and limb formation [25-28, 28]. The influence of GDF-5 alone or in 
combination with insulin on the development of TE cartilage constructs either made from 
primary or from expanded chondrocyte was investigated in this thesis (chapter 5). 
As articular cartilage is known as a steroid hormone-sensitive tissue, intensive research has 
been previously done on the role of estrogen and androgens and other steroids on the growth 
plate cartilage and longitudinal bone growth [29-31]. In cartilage engineering, only little is 
known about the potential of steroid hormones. Therefore, the effects of testosterone, estrogen 
and dehydroepiandrosterone on the development of cartilage TE constructs were investigated 
(chapter 6). 
 
Oxygen conditions in tissue engineering of cartilage 
Despite the fact that in articular cartilage an oxygen partial pressure of 10% and lower is 
observed, most cell culture experiments including cartilage engineering approaches are 
conducted using an oxygen concentration of 21%. As a third aspect of this thesis, the effects 
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of differential oxygen partial pressure (5% and 21% O2) on the development of cartilage TE 
constructs were investigated. These experiments were combined with the effects of 
morphogens like insulin and GDF-5 (see chapter 5) and sexual steroid hormones (see chapter 
6) (chapter 7). 
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Materials and Methods 
Lipid matrices production (chapter 3) 
For the aseptic production of insulin-loaded matrices, Dynasan 116 (glycerol tripalmitate), a 
kind gift from Sasol (Witten, Germany), was sterilized for 2 hours at 160°C. Subsequently 
crystallization of the lipid in the stable beta-orientation was achieved by tempering the molten 
lipid for 3 days at 55°C. Lipid modification was investigated by scanning calorimetry using a 
2920 differential scanning calorimeter (TA Instruments, Alzenau, Germany) at a heating rate 
of 5 K/min. The lipid was powdered in a mortar and sieved through a sieve with a pore size of 
106 µm under aseptic conditions. For the preparation of the desired insulin/lipid powder 
mixtures, 58.84mg human insulin (Sanofi-Aventis, Frankfurt/Main, Germany) were dissolved 
in 300 µl 0.01N HCl (Carl Roth, Karlsruhe, Germany) and 11 ml double-distilled water were 
added. The solution was filtered through a 0.22 µm filter (Corning, Schiphol-Rijk, 
Netherlands) and the concentration of insulin was determined by HPLC (see insulin 
measurements). Calculated amounts of the insulin solutions required for the desired 
insulin/lipid ratios were added to mortars filled with sterile Dynasan 116® (glycerol 
tripalmitate). The mixtures were freeze-dried in a desiccator, cooled with dry ice, and 
evacuated using a RV5 two-stage pump (Edwards, Crawley, Sussex, UK) for 24 hours under 
aseptic conditions. The dried powder mixtures were manually homogenized in a mortar. For 
the manufacture of lipid matrix cylinders, a set of 2 mm diameter cylindrical punches and a 
die were machined from hardened steel and V4A steel, respectively. Cylindrical matrix discs 
(2 mm height, 2 mm diameter) were obtained by manual compression of accurately weighed 
amounts of the insulin-loaded lipid powder in the die, applying a force of approximately 250 
N for 10 s. Cylinders with an average weight of 6.3±0.60 mg were used for the experiments. 
The matrices were visualized by scanning electron microscopy (SEM). For this procedure, 
samples were mounted on aluminum stubs with conductive carbon tape and coated with gold-
palladium. All micrographs were obtained at 10kV on a DSM 950 (Zeiss, Oberkochen, 
Germany). 
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Solid lipid templated scaffolding (chapter 4) 
The scaffolds (chapter 4) were prepared by a recently developed anhydrous solid lipid 
templating technique using solid lipid microparticles as porogens as previously described [23, 
24]. Solid lipid templating combines the principles of phase separation and porogen leaching 
to generate spongy scaffolds [24]. In brief, Resomer RG756 (PLGA), synthesized from 75% 
lactic acid (LA) and 25% glycolic acid (GA), kindly provided by Boehringer Ingelheim 
(Ingelheim, Germany) was dissolved in ethylacetate. If applicable an appropriate amount of 
crystalline bovine insulin (Sanofi-Aventis, Frankfurt, Germany) was suspended in the RG756 
solution. Solid lipid microparticles were further suspended under ice cooling with the polymer 
solution. The homogeneous dispersion was transferred into Teflon molds (1.9 cm x 1.9 cm x 
1.2 cm) with a cylindrical cavity of 0.8 cm in diameter. After a pre-extraction treatment step 
in n-hexane at 0°C, the molds were submerged in warm n-hexane to induce solvent extraction 
followed by the precipitation of the polymer and extraction of the lipid porogen. The resulting 
porous, cylindrical polymer constructs were allowed to cool in cold (0°C) n-hexane and were 
removed from the molds. After drying under vacuum for 48 h, the constructs were cut into 2 
mm slices, which were then designated as scaffolds. 
 
Insulin measurements (chapter 3 and 4) 
The drug loading of the matrices (chapter 3) and the scaffolds (chapter 4) was determined by 
HPLC. Matrices/scaffolds were dissolved in 600 µl chloroform (Merck, Darmstadt, Germany) 
each and insulin was then extracted with 600 µl 0.01N HCl (Carl Roth, Karlsruhe, Germany). 
After 10 s of mixing on a vortex mixer (Genie-2, Scientific Industries, NY; USA), phase 
separation was achieved by letting the mixture settle for 10 minutes. This procedure was 
repeated two times and followed by centrifugation at 1600 g (5415R, Eppendorf, Hamburg, 
Germany). 
The insulin content of the aqueous phase was analyzed by HPLC analysis, using an HPLC 
system with a degasser (Knauer, Berlin, Germany), LC-10AT pump, FCV-10ATvp gradient 
mixer, SIL-10Advp autosampler, CTO-6a oven, SPD-10AV UV-Detector, RF-551 
fluorescence detector and SCL-10Avp controller (all from Shimadzu, Duisburg, Germany). 
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100 µl of the insulin solutions were analyzed at 37°C using a C18-reversed phase precolumn 
(LC318, 4,6mmx20mm, Supelco, Bellefonte, USA) combined with an analytical C-18 
reversed phase column (Supelcosil, LC318, 4.6 mm x 250 mm; Supelco, Bellefonte, USA) 
and a linear gradient method (mobile phase A: 90% H2O, 10% acetonitrile, 0.1% TFA; mobile 
phase B: 90% acetonitrile, 10% H2O and 0.1% TFA) with a flow rate of 1 ml/min. A linear 
gradient from 20% to 36% B over 24 min was applied. The chromatograms were recorded at 
wavelengths of 210 nm and 274 nm (UV-detection) and fluorescence detection was carried 
out at 274 nm excitation and 308 nm emission. 
Cell culture media from the four-weeks trial (chapter 3) were collected at the times of media 
change every two to three days and frozen at -80°C. The insulin content was determined by 
enzyme-linked immunoassay (ELISA) in appropriate dilutions. The absorption was measured 
at 450 nm on a plate reader (Shimadzu, Duisburg, Germany). Possible adsorption of insulin 
on the surfaces of the well-plates was minimized by the use of FBS in the releasing cell 
culture media [32]. Previous studies employing two similar culture systems indicated that 
when exogenous insulin was applied at the time of media change and remaining insulin was 
assessed at the next medium change after 2-3 days, approximately 75-100% of the originally 
applied insulin were measured by ELISA [33]. 
 
Chondrocyte isolation 
Knee joints from three-months-old bovine calves were obtained from a local slaughterhouse 
(EGN Vilshofen, Vilshofen, Germany or SBL Landshut, Landshut, Germany) within 6-12 
hours of slaughter. Fresh articular cartilage was gained from the surface of the femoral 
patellar groove. The cartilage was cut into small pieces and primary chondrocytes were 
isolated by enzymatic digestion with collagenase type II, obtained from Worthington 
(CellSystems, St.Katharinen, Germany). The digest was filtered through a 149 µm filter 
(Spectrum, Rancho Dominguez, CA, USA)., centrifuged at 1200 rpm for 5 minutes, and 
washed three times with PBS (Gibco-Invitrogen, Karlsruhe, Germany) [16]. Isolated cells 
were resuspended in culture medium (DMEM) containing 4.5 g/l glucose, 584 mg/l 
glutamine, 10% FBS, 50 U/ml penicillin, 50 μg/ml streptomycin, 10 mM HEPES, 0.1 mM 
non-essential amino acids, 0.4 mM proline (all from Gibco-Invitrogen, Karlsruhe, Germany), 
and 50 μg/ml ascorbic acid (Sigma-Aldrich, Taufkirchen, Germany). The cell number was 
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determined by cell counting using a hemocytometer and an inverted phase-contrast 
microscope. Pipettes, petri dishes, falcon tubes, and well plates were purchased from 
(Corning, Schiphol-Rijk, Netherlands). 
 
Cultivation under 21% and 5% oxygen partial pressure (chapter 6,7) 
Cells were kept under an atmosphere of 21% O2, 5% CO2, and 74% N2 in a CO2-regulated 
incubator (Heraeus Instruments, Hanau, Germany) or under 5% O2, 5% CO2, and 90% N2 in 
also an CO2-regulated incubator (Heraeus Instruments, Hanau, Germany). For the reduced 
oxygen atmosphere a ready-made gas mixture was used containing 5% O2, 6% CO2, and 90% 
N2 (Linde, Pullach, Germany). The slight increase in CO2 from 5% to 6% partial pressure 
allowed the CO2 sensor in the incubator adaptive control of gas concentration. 
 
Chondrocyte expansion (chapter 5-7) 
Primary chondrocytes were seeded in 150cm2 cell culture flasks (7.500 cells/cm2) (Corning, 
Schiphol-Rijk, Netherlands) and cultivated in medium described above to confluence over 13 
days. The cells (passage 1) were washed three times with PBS and trypsinized with trypsin 
0.25% (Gibco-Invitrogen, Karlsruhe, Germany), After centrifugation and resuspension in 
chondrocyte medium they were counted (see above, 10-fold increase in cell number) and 
seeded again in 150cm2 cell culture flasks. After 8 days they were confluent again (passage 2 
= expanded chondrocytes, 9-fold increase in cell number), harvested as described above and 
seeded onto the PGA scaffolds. 
 
In vitro cell culture 
Cell seeding (Fig. 2) was performed in self-made spinner flasks (250 ml volume, 6 cm bottom 
diameter, side arms for gas exchange). Polyglycolic acid (PGA) non-woven meshes (12-14 
µm fiber diameter; 96% porosity; 62mg/cm3 bulk density; initial molecular weight of PGA 
approx. 70 kDa) [34] were obtained from Albany International (Mansfield, MA, USA) and 
die-punched into discs 5 mm in diameter and 2 mm thick (scaffolds). Scaffolds were threaded 
onto needles (10 cm long, 0.5 mm diameter, from Unimed, Lausanne, Switzerland) and held 
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in place with small pieces of silicone tubing (1 mm long, from Cole Palmer, Niles, IL, USA),. 
Four needles with two scaffolds apiece were inserted into a silicone stopper (Schuber & 
Weiss, München, Germany), which was placed into the mouth of a spinner flask containing a 
magnetic stir bar. The cell suspension with 5*106 isolated chondrocytes per scaffold (i.e., 
40*106 cells per flask) in 110 ml of culture medium was filled into the flask. Flasks were 
placed in an incubator at 37 °C, 21% O2, 5% CO2, and 74% N2 in a CO2-regulated incubator 
(Heraeus Instruments, Hanau, Germany) and 95% humidity; stirring with 50 rpm on a 
magnetic stirrer (Bellco, Vineland, NJ, USA) for two days allowed for cell attachment. 
 
 
Fig. 2:  Experimental tissue engineering set-up including seeding in spinner flask bioreactors and cultivation in 
well-plates. 
 
Each scaffold was then placed in a 6-well plate (Corning, Schiphol-Rijk, Netherlands) filled 
with 6 ml of culture medium (same medium as above except for 1% FBS instead of 10%); 
plates were placed on an orbital shaker at 50 rpm (SO5, Stuart Scientific, Surrey, UK).  
For the reduced oxygen culture conditions an additional incubator 
After one day, morphogens were added to the wells and from then on with each medium 
change. In all groups, medium was replaced three times per week. 
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In vitro cell culture and controlled release of insulin 
Cell culture with lipid matrices (chapter 3) 
Two independent studies were conducted: In the first study, which was conducted over two 
weeks and which in the following is designated “two-weeks trial”, cell-polymer constructs 
were cultured in the presence of matrices loaded with 2% (m/m) insulin; groups with 
unloaded matrices (0%) or no matrices served as controls. For further comparison, a fourth 
group was included receiving exogenous insulin at 2.5 µg/ml with each medium change 
(concentration eliciting maximum response based on previous studies [18]). Four individual 
constructs were cultured per matrices group, two constructs in each of the no-matrices groups. 
In the second study, conducted over four weeks and designated “four-weeks trial”, cell-
polymer constructs were cultured in the presence of matrices with three different loading 
concentrations of insulin (0.2%, 1%, 2% (w/w)) or unloaded matrices (0%). Four individual 
constructs were cultured per group. 
Cell seeding and cell culture on solid lipid templated scaffolds (chapter 4) 
The PLGA scaffolds were disinfected in 70% ethanol for 2 hours. Afterwards they were 
thoroughly rinsed three times in PBS. The treated scaffolds were transferred into bioreactors 
and pinned onto needles. To reduce effects from potential burst release of insulin from the 
scaffolds and for improved cell attachment scaffolds were rinsed in the bioreactors with 
complete culture medium under stirring for 24 hours. Subsequently, medium was changed and 
a cell suspension containing 5 x 106 chondrocytes per scaffold was added and stirred at 80 
rpm in a humidified (37 °C / 5% CO2) incubator for two days to allow for cell attachment to 
the polymers. Cell-polymer constructs were transferred into 6-well plates (one construct and 6 
ml culture medium per well) and cultured for three weeks on an orbital shaker at 50 rpm. 
Medium was completely exchanged three times per week. Four independent constructs were 
cultured per group. Three different groups with different concentrations of insulin loading 
were investigated (designated as I0.1%, I0.7%, and I1.7%) and compared to an unloaded 
control group (control). In a further control group, unloaded scaffolds received exogenous 
insulin with each medium change at a concentration of 1.4 mg/ml, based on theoretical 
calculations of the maximum release rate from the insulin-loaded scaffolds (I1.4)  
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The concentration of exogenously applied insulin was calculated on the basis of the medium 
loading rate of 0.69% insulin (w/w) and an average scaffold mass of 11mg. The resulting 
loading mass of 76µg insulin per mesh was divided by 9 media changes during the culture 
period. The resulting mass of about 8.4µg insulin released between each media change 
divided by 6ml of cell culture medium gave a concentration of about 1.4µg/ml insulin that 
was taken as exogenous insulin control. In this calculation loss of insulin during the procedure 
of cell seeding in the bioreactor, burst release or incomplete release were not taken into 
account. 
In order to control for a potential insulin burst release, in two further groups single insulin 
doses, either 10 or 200 µg/ml, were applied after transfer into the 6-well-plates (I10µ and 
200µ). After that, these groups received only standard medium without insulin. 
 
Biochemical analysis of the engineered tissues 
Analytical assays were performed as previously described [18]. In brief, cell-polymer 
constructs were weighed (= wet weight, ww) and cut in half. One part was freeze-dried and 
digested by papain solution (3.2 U/ml in buffer) for 18 h at 60°C. The cell number was 
determined measuring the DNA content using Hoechst 33258 (Polysciences, Warrington, PA, 
USA) dye in a fluorometrical assay [35]. The sulfated glycosaminoglycan (GAG) content was 
determined spectrophotometrically at 525 nm as chondroitin sulfate  (ICN, Aurora, Ohio, 
USA) after reaction with dimethylmethylene blue (Sigma-Aldrich, Taufkirchen, Germany) 
[36, 37]. Hydroxyproline content was measured spectrophotometrically at 550 nm after acid 
hydrolysis and reaction with chloramine-T (Merck, Darmstadt, Germany) and p-
dimethylaminobenzaldehyde (Merck, Darmstadt, Germany) [38]. The total collagen amount 
could be calculated using a hydroxyproline to collagen ratio of 1:10 [39]. 
 
Histology of the engineered tissues 
The constructs were fixed in 2% glutaraldehyde (Merck, Darmstadt, Germany) for 30 minutes 
and stored in 5% formalin. After fixation, the tissues were embedded in paraffin and sliced 
into 5 µm sections. The deparafinized sections were subjected to a hematoxylin, fast green 
and safranin-O staining (Sigma-Aldrich, Taufkirchen, Germany)  [40]. 
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Immunohistochemistry of the engineered tissues 
The constructs were fixed in a mixture of methanol/PBS and 9% formaldehyde (Sigma-
Aldrich, Taufkirchen, Germany). They were incubated in ascending concentrations of sucrose 
solution up to 40% and frozen in Tissue-Tek (Sigma-Aldrich, Taufkirchen, Germany). Frozen 
samples were cryosectioned at 10µm in a cryostat (HM550OMP, Microm, Walldorf, 
Germany). Dried sections were rehydrated in PBS containing 0.1% tween-80 (Sigma-Aldrich, 
Taufkirchen, Germany) (PBS/tween) and processed with a pepsin (Sigma-Aldrich, 
Taufkirchen, Germany) digestion. Non-specific antigen binding was blocked by a 5% normal 
horse serum in PBS. Primary antibody solution was spreaded on the slides and incubated 
overnight. Antibody solution was dissolved with PBS/tween in a ratio of 1:1000 for collagen 
type I antibody (col-1) (Sigma-Aldrich, Taufkirchen, Germany) and 1:6 for collagen type II 
antibody (CIIC1) as previously described [41], for control sections pure PBS containing 0.1% 
tween-80 was used. Anti-collagen type II antibody (CIICI) developed by Rikard Holmdahl 
and Kristofer Rubin was obtained from the Developmental Studies Hybridoma Bank 
developed under the auspices of the NICHD (University of Iowa, Department of Biological 
Sciences, Iowa City, USA). After a washing procedure slides were incubated with a 
secondary biotinylated antibody for 30 minutes and washed with PBS/tween vigorously. 
Staining procedure was performed following the manufacturer operating procedures using a 
Vectastain ABC-kit and a DAB-kit for the avidin-biotin-peroxidase complexes formation. 
Secondary biotinylated antibody (BA-1400) anti-mouse anti-rabbit antibody, Vectastain 
ABC-kit and DAB staining-kit were from Vector Laboratories (Linaris, Wertheim-Bettingen, 
Germany). 
Reverse transcription polymerase chain reaction (RT-PCR) 
RT-PCR analysis was performed as described elsewhere [42]. In brief, native and engineered 
cartilage blocks were frozen in liquid nitrogen and lyophilized. RNA was extracted using 
RNA-Bee (Biozol, Eching, Germany) according to the single-step acid-phenol guanidinium 
method. cDNA synthesis was performed by using Superscript RNase H-reverse transcriptase 
(Invitrogen, Karlsruhe, Germany) in the presence of oligo-dt primers. Primers were sequenced 
as detailed in [42]. RT-PCR was conducted using Light Cycler analysis with Light Cycler 
Kits (Roche, Mannheim, Germany). The level of each target gene was normalised to the 
reference gene glyceraldehyde phosphate dehydrogenase (GAPDH).  
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Statistical analysis 
Statistical significance was assessed by one-way analysis of variance ANOVA in conjunction 
with Tukey’s studentized range test using SPSS 12 for Windows from SPSS Software 
(Munich, Germany). 
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 Introduction 
The field of tissue engineering [1] aims at the regeneration of mechanical and functional body 
tissue or organ defects that cannot be sufficiently cured by self-healing processes. One 
strategy in tissue engineering is to seed and culture cells on 3-D scaffold structures in vitro in 
order to generate tissue constructs for implantation. Cell proliferation and differentiation as 
well as the formation of an adequate extracellular matrix (ECM) in an in vitro culture largely 
depend on the supplementation of growth factors and other morphogens [20]. In addition 
growth factors can strongly improve the integration of the engineered tissue after 
implantation. These effects render growth factors an important tool for tissue engineering 
purposes, however, their efficacy is limited by their short half-lives and their potential toxicity 
at systemic levels [20]. To overcome these problems the use of protein carriers that ensure a 
sustained release and at the same time retain the biological activity of the growth factors is 
desirable [21]. Unfortunately, protein stability is easily compromised during the manufacture, 
storage, and drug release (Schwendeman et al., 1996). For example, for the well established 
biocopolymer poly(lactic-co-glycolic acid) (PLGA) it has been demonstrated that degradation 
products from the release matrix can influence protein stability due to changes in the 
microclimate of the microspheres during degradation, e.g., higher osmotic pressure or acidic 
environment [44, 45]. In order to overcome such problems, stabilizing additives were 
introduced such as Mg(OH)2 [46], Ca(OH)2 [47], and, especially for insulin, zinc salts [48, 48-
50]. The latter was additionally used to prolong the release of insulin [51] [32] [52]. As an 
alternative approach, controlled release systems based on lipids as a matrix material have 
recently attracted increasing attention, as they avoid detrimental effects of breakdown 
products of the biomaterial [53-55]. However, the processes used for the production of a lipid 
matrix often include organic solvents likely resulting in organic-water interfaces, which in 
turn are known as destabilizing factor for proteins [56]. We recently developed cylindrical 
matrices based on solid triglycerides, especially designed for the purpose of a long-term 
release [57]. For the production of these protein-loaded matrices neither emulsions with 
organic solvents, surfactants nor ultrasonification are needed, which in other systems may 
lead to a loss of bioactivity of the incorporated proteins [22]. These matrices may not only be 
of major interest in the field of tissue engineering, but also can be loaded with proteins and 
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other types of drugs for the local treatment of tissues such as needed in the treatment of brain 
cancer [57] or neurodegenerative CNS diseases. 
Previously, we established a 3-D cartilage engineering culture (Fig. 1) that can be utilized as a 
test system for sustained-release carriers [18].  
Readily available insulin is used as a model protein; insulin was demonstrated to have strong 
anabolic effects on engineered cartilaginous constructs similar to those of insulin-like growth 
factor-I (IGF-I). The model provides quantifiable data and responds sensitively to 
supplemented insulin in a dose-dependent manner over a cultivation period of several weeks 
[18]. Even if sustained-release carriers are typically applied in an in vivo situation, this 3-D 
culture offers the opportunity to evaluate newly developed release systems with regard to their 
effects within a defined tissue engineering setting. 
In this study, insulin-loaded triglyceride matrices were manufactured in order to investigate 
the biological effects of released insulin in the 3-D cartilage engineering culture. The first 
specific aim was the determination of the release kinetics of matrices with varying amounts of 
incorporated insulin. Further specific aims were the analysis of the effects of released insulin 
on the tissue construct weight, cell number, and amounts of ECM components, namely 
glycosaminoglycans and collagen, within the engineered tissue. 
Results 
Lipid matrices 
The manufactured insulin-loaded matrices had a well-defined cylindrical geometry. 
Examination by scanning electron microscopy revealed a generally smooth surface (Fig. 3A). 
After sterilization and tempering, differential scanning calorimetry analysis showed only the 
endothermic peak caused by the melting of the stable β-modification of glycerol tripalmitate 
(same peak as before treatment) indicating that complete crystallization of the lipid in the 
stable orientation was achieved (Fig. 3B).  
Insulin loadings of the matrices were 0.20% (w/w) ± 0.003, 1.08% ± 0.043, and 2.08% ± 
0.114, as determined by HPLC, and correlated well with the intended and designated insulin 
contents of 0.2%, 1%, and 2%, respectively. 
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 Fig. 3: (A) Scanning electron microscopy image of the manufactured cylindrical matrix, loaded with 
human insulin. (B) Determination of crystallinity of untreated glycerol tripalmitate (-) and sterilized and 
tempered glycerol tripalmitate (- -) by differential scanning calorimetry. The thermograms were recorded 
at a heating rate of 5K/min. Only the endothermic peak for the melting of the stable β-modification of 
glycerol tripalmitate was detected before and after treatment, indicating that complete crystallization in 
the stable modification was achieved also after treatment. 
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Two-weeks trial 
In the two-weeks trial, a significant 1.9-fold increase in wet weight was detected for the cell-
polymer constructs cultured for two weeks in the presence of the insulin-loaded matrices (2%) 




















Fig. 4: Effects of unloaded and insulin-loaded lipid matrices on the wet weight of tissue engineered cartilage 
in the two-weeks trial. Statistically significant differences to the control and matrices control (unloaded matrices) 
are denoted by * (p<0.05). Data represents the average ± SD of four independent measurements for the 
matrices groups and two independent measurements for the control and insulin 2.5µg/ml groups. 
 
The wet weight of the unloaded matrices group was not significantly different from the 
control group with no matrices. The constructs receiving exogenous insulin (2.5 µg/ml) 
showed similar wet weights as the constructs cultured in the presence of the insulin-loaded 
matrices (Fig. 4).  
The insulin-loaded matrices also significantly increased the absolute amounts of the ECM 
components GAG and collagen in the cell-polymer constructs (2.4-fold and 3.2-fold, 
respectively) and the GAG and collagen content per cell (1.8-fold and 2.5-fold, respectively), 
as compared to the control group with unloaded matrices (Table 1). The cell number per wet 
weight was decreased to 67% (Table 1); a lower cell density is commonly observed in more 
mature engineered cartilaginous constructs [18]. All values obtained for the constructs grown 
in the presence of the insulin-loaded matrices were on the same order of magnitude as the 
values obtained for the constructs receiving exogenous insulin (Table 1).  
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 control insulin  matrices  matrices  











GAG per cell [pg] 181±35.9 347±54.2 * 200±10.1 368±47.7 *
collagen [mg] 0.39±0.113 1.3±0.24 * 0.36±0.047 1.2±0.34 *
collagen per cell [pg] 63.1±4.09 171±8.1 * 58.0±1.93 144±29.0 *
cell number per wet 
weight [1/µg] 
202±31.4 96.8±10.27 * 174±25.3 117±11.3 *
     
Tab. 1:  Effects of unloaded and insulin-loaded lipid matrices on tissue-engineered cartilage in the two-weeks 
trial. Data represents the average ± SD of four independent measurements for the matrices groups and two 
independent measurements for the control and insulin 2.5µg/ml groups. Statistically significant differences to 
the control and matrices control (unloaded matrices) are denoted by * (p<0.05). 
 
For all parameters investigated, no significant differences were detected between the two 
control groups cultured in the absence of matrices or in the presence of unloaded matrices 
(Table 1).  
The histological analysis of the constructs correlated well with the obtained quantitative 
biochemical data. All cross-sections of the constructs appeared to be cartilaginous with round 
chondrocytes in lacunae surrounded by large areas of extracellular matrix deposition. 
However, the control group constructs cultured without insulin had a smaller, more fractured 
appearance compared to those of the insulin groups. Constructs from the groups cultured 
either in the presence of insulin-loaded matrices or exogenous insulin showed a more regular 
and coherent GAG distribution when stained red with safranin-O (data not shown).  
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Released insulin was sampled at the times of media change directly from the well plates of the 
cell culture of the four-weeks trial. Thus, the collected insulin had been released over a period 
of two to three days. Over the first 3 days, a small burst release was observed for matrices 2% 
(10.3%), matrices 1% (23.8%), and matrices 0.2% (21.6%). Within the first 12 days, the 
matrices continuously liberated up to 67% (matrices 2%), 89% (matrices 1%) and 99% 
(matrices 0.2%), respectively, of the total loaded protein (Fig. 5A). Insulin concentrations at 
the times of media change within the first 12 days were between 0.4 and 5.7µg/ml for 
matrices 2% (day 12, day 8), between 0.9 and 3.4 µg/ml for matrices 1% (day 12, day 8), and 
between 0.01 and 1.0 µg/ml for matrices 0.2% (day12, day 8) (Fig. 5B).  
Generally, after day 12, lower amounts of insulin were released. However, at the times of 
media change the insulin concentrations were still above 0.005 µg/ml in the groups of the 
matrices 1% (except for day 19, 0.004 µg/ml) and matrices 2% (except for day 24, 
0.004 µg/ml) (Fig. 5B). Even on day 29, the last day of this study, insulin concentrations of 
0.019 µg/ml and 0.025 µg/ml were observed for matrices 1% and matrices 2%. In contrast, 
insulin concentrations in the group of the matrices 0.2% were always below 0.002 µg/ml after 
day 17 (Fig. 4B). 












































 Fig. 5: (A) Cumulative release of insulin from lipid matrices in the four-weeks trial under cell culture 
conditions determined by ELISA. (B) Insulin concentrations measured in the cell culture medium at the time 
of media change every second or third day determined by ELISA. Data represents the average ± SD of four 
independent measurements. 
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Wet weights and cell number 
All cell-polymer constructs cultured in the presence of insulin-loaded matrices exhibited 
significantly increased wet weights after four weeks of culture (54.5 – 100 mg), as compared 
to control constructs cultured in the presence of unloaded matrices (31 mg). The dose-
dependent increases of the matrices groups were 1.7-fold, 2.7-fold, and 3.2-fold, respectively. 
Values for the matrices 1% and 2% were significantly higher than those for matrices 0.2% 
(Fig. 6A). 
The cell number per wet weight was reduced in all constructs receiving released insulin, as 
compared to the constructs receiving no insulin. A dose-dependent trend was observed with 
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 Fig. 6: Effects of insulin-loaded matrices on the wet weight (A), and the cell number per wet weight (B) of 
engineered cartilage after 28 days in the four-weeks trial. Data represents the average ± SD of four 
independent measurements. Statistically significant differences to the matrices control (unloaded matrices) are 
denoted by * , to the matrices 2% group by °(p<0.05). 
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 Fig. 7: Effects of insulin on the absolute amount of collagen per construct (A), and on the amount of 
collagen per cell in engineered constructs (B) in the four-weeks trial. Data represents the average ± SD of 
four independent measurements. Statistically significant differences to the matrices control (unloaded 
matrices) are denoted by *, to the matrices 2% group by ° (p<0.05). 
 
Collagen and glycosaminoglycans 
Insulin released from the lipid matrices dose-dependently increased the absolute amount of 
collagen within the cell-polymer constructs. Increases were between 4-fold (4.4 mg for 
matrices 2%) and 2-fold (2.2 mg for matrices 0.2%), as compared to constructs receiving no 
insulin (1.1 mg) (Fig. 7A). The collagen content per cell was also increased by released 
insulin; an almost 3-fold increase was observed for matrices 2% (Fig. 7B).  
Similar observations were made for the GAG content: Absolute amounts of GAG were 
increased in the matrices 1% and 2% groups (up to 3.5 mg), as compared to the unloaded 
matrices group (1.2 mg). The matrices 0.2% only led to a slight, but not significant increase 
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(Fig. 7A). The same applied to GAG content per cell, which was increased 2.2-fold in the 
matrices 1% and 2% groups (Fig. 7B). For all parameters, no significant differences could be 





matrices matrices matrices matrices















matrices matrices matrices matrices













 Fig. 8: Effects of insulin on the absolute amount of glycosaminoglycans (GAG) per construct (A), and on 
the amount of GAG per cell in engineered constructs (B) in the four-weeks trial. Data represents the 
average ± SD of four independent measurements. Statistically significant differences to the matrices 
control (unloaded matrices) are denoted by *, to the matrices 2% by ° (p<0.05). 
Histology 
Histological cross-sections showed an increasing construct size with increasing insulin 
content of the matrices correlating with the construct weights (Fig. 6A, Fig. 9). In all cross-
sections, round chondrocytes in lacunae surrounded by large areas stained red with safranin-O 
for GAG were detected. However, the constructs grown in the presence of matrices 1% and 
2% exhibited a more even distribution of GAG, as compared to the constructs of groups with 
matrices 0.2% and unloaded matrices, which showed an irregular GAG distribution with 
distinct areas containing no safranin-O stain (Fig. 9). 
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Fig. 9: Glycosaminoglycan (GAG) distributions in cross-sections of tissue-engineered constructs. GAG was 
stained red with safranin-O (appears dark gray in the black & white print). 
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Discussion 
Growth factors, cytokines and morphogens are powerful protein molecules that, if adequately 
released from carrier systems, potentially play a key role in many tissue engineering 
applications. Unfortunately, in controlled release studies in general, processing during the 
manufacture of the carriers, storage, and the release itself often strongly compromise protein 
stability [58]. Therefore, in the development of new release systems it is paramount to 
determine not only the release kinetics by standard assays such as ELISA, but also to 
determine the bioactivity of the released protein in a relevant environment. In this study, 
recently developed cylindrical matrices were investigated with regard to the biological effects 
of released protein. The lipid devices require neither stabilizing additives within the matrix 
nor possibly detrimental organic-water interfaces during the production process. Insulin 
served as model protein and its effects were determined in a recently established cartilage 
engineering test culture [18]. 
 
Cylindrical lipid matrices were produced from glycerol tripalmitate by manual compression 
with an insulin load of 0.2%, 1, or 2%. As a possible change in lipid modification could have 
an impact on release characteristics, the lipid matrices were subjected to differential scanning 
calorimetry analysis. It was demonstrated that no detrimental effects occurred during 
processing; the glycerol tripalmitate showed crystallization exclusively in the stable β-
modification before and after treatment. 
 
In the two-weeks trial, distinct beneficial effects on tissue construct development were 
observed elicited by released insulin. Increases in construct wet weight and amounts of ECM 
components, as compared to controls receiving no insulin, were on the same order of 
magnitude as for constructs in the group receiving exogenous insulin at a concentration of 2.5 
µg/ml (Fig. 4, Tab. 1); this concentration was previously shown to elicit the maximum 
response in the same culture system [18]. Furthermore, the constructs grown in the presence 
of the empty control matrices were not significantly different from the control constructs 
cultured in the absence of any matrices only in basal medium, indicating that the lipid 
matrices themselves had no effects on tissue construct development (Fig. 4, Tab. 1). 
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Therefore, in the four-weeks trial the control group cultured only in basal medium was 
omitted; the insulin-loaded matrices were compared to unloaded controls. 
 
For all three different insulin loadings, an insulin burst release of only 10-24% was detected 
within the first three days (Fig. 5A). In preliminary experiments, we could show that high 
concentrations of exogenously applied insulin (up to 50 µg/ml) only during the first days of 
culture, i.e. simulating a burst release at concentrations by far exceeding the concentrations 
reached in the presented study, resulted in distinctly inferior constructs compared to a 
continuous supply of insulin at concentrations below 0.01 µg/ml over 21 days (data not 
shown). Within the presented study, in general, higher amounts (>0.4 µg/ml) of insulin were 
released during the first twelve days from the matrices with higher loadings and during the 
first eight days from the matrices with the lowest loading. Although the released amounts 
dropped afterwards, for the matrices 1% and 2% still concentrations above 0.005 µg/ml of 
insulin were achieved (Fig. 5B). In preliminary experiments, 0.005 µg/ml was the minimum 
insulin concentration eliciting a biological response in the 3-D cartilage engineering culture 
(data not shown). In the group cultured in the presence of the matrix with the lowest loading, 
insulin concentrations were always distinctly below this concentration after day 17 (Fig. 5B). 
The measured concentrations of the released insulin were well reflected by the effects on the 
quality of the engineered cartilage constructs. The culture in the presence of the lipid matrices 
0.2% resulted in significant increases of the wet weight and collagen content of the constructs, 
furthermore in a beneficial decrease of the cell number per wet weight, as compared to the 
unloaded matrices controls (Fig. 6, Fig. 7). This indicated that even the comparably low 
concentrations of insulin released from these matrices were sufficient to elicit relevant 
biological effects. 
 
Even stronger effects were observed for the matrices 1% and 2%: Large improvements in wet 
weight, cell number per weight, collagen and GAG amounts and also differences in the 
histological appearance were detected. Even the amounts of the ECM components per cell 
were distinctly increased (Fig. 6- Fig. 8). The effects on wet weight and amounts of ECM 
components were significantly larger than those of the matrices 0.2%, which was in 
agreement with the release data. Only a small trend in favor of the matrices with the highest 
loading (2%) was observed, but no significant differences could be detected between 
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constructs grown in the presence of matrices 1% and 2%, indicating that the minor differences 
in release data were also of minor relevance for the development of the constructs. 
In the presented study, the cartilage engineering culture was successfully employed to prove 
the bioactivity of the released insulin. Up to now, the only methods to directly investigate the 
efficacy of an insulin releasing device over a period of weeks involved in vivo assays such as 
the determination of the blood glucose level in rats over a period of 14 days [50]. Here, it was 
demonstrated that the cartilage engineering in vitro assay facilitates the testing of controlled 
release devices with regard to their biological efficacy in a complex system without the need 
for the expense of laboratory animals.  
 
In conclusion, in this study we demonstrated the sustained release of bioactive insulin from 
cylindrical lipid matrices. The released insulin elicited strong dose-dependent effects on tissue 
engineered cartilage. The lipid matrices, preserving bioactivity of incorporated and released 
proteins, are suggested as a suitable carrier system for growth factors and morphogens in 
regenerative medicine. 
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Introduction 
In the field of tissue engineering [1] new strategies and techniques have been developed for 
the growth of functional tissues in-vitro or the enhanced repair of damaged tissues in-vivo. 
Recent tissue engineering approaches utilize biocompatible, biodegradable polymeric cell 
carriers (scaffolds) as an artificial extracellular matrix (ECM) in combination with 
morphogenetic effectors like growth factors [12]. The success of those tissue engineering 
approaches often depends on the suitability of the scaffold and the method of growth factor 
delivery to the cells within the regenerating tissue. In particular the emulation of natural 
growth factor production in developing or regenerating tissues became of major interest for 
tissue engineering applications [19].  
 
However, the administration and utilization of proteinic growth factors is limited by their 
short half-lives and their potential toxicity at systemic levels [20]. This makes protein carriers 
desirable, which could ensure a sustained release and at the same time retain the biological 
activity of the growth factors [21]. The adaption of drug delivery systems for tissue 
engineering application led to the development of promising controlled release devices, which 
guaranteed adequate growth factor concentrations at the site of action over an extended period 
of time. They were developed by incorporation of the growth factor in an appropriate carrier, 
which made it possible to apply this combination of growth factors and their carriers at the 
site of action [13]. Recently, in tissue engineering applications also the cell carrier system has 
been utilized as release device, e.g., providing growth factors embedded in a hydrophilic gel 
[59], which enabled accelerated diffusion of the growth factor, or manufactured in a double 
emulsion process [19]. However, it has to be kept in mind that in many manufacturing 
processes of protein release devices the protein stability may be compromised, e.g., by 
elevated temperatures or at organic-water interfaces, which lead to protein aggregation and 
changes in protein structure, in turn resulting in a loss in bioactivity [56, 58]. Therefore, in the 
development of new protein release devices the evaluation with regard to bioactivity in a 
relevant application-oriented setting is a sine qua non.  
 
In tissue engineering applications, also solid macroporous scaffolds have been used as a 
release device[60-67]. In general, such scaffolds can be produced by various techniques, such 
as salt leaching [68, 69], fibrous fabric processing [70], gas foaming [71], thermally induced 
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phase separation [72]. Recently, in our group the manufacturing of macroporous scaffolds 
using the newly developed lipid-templating technique has been demonstrated [23, 24]. 
In this study, the suitability of the latter scaffolds as protein release system was investigated. 
Insulin served as model protein and was incorporated into the scaffolds during manufacture. 
The scaffolds were evaluated within an established insulin-sensitive cartilage engineering 
culture in vitro [18, 43]. 
Results 
Insulin loading 
The insulin content of the scaffolds was determined by a two phase extraction and phase 
separation method followed by HPLC analysis as described in chapter 2. Originally, insulin 
contents of 0.1% - 2.5% were aimed at. Loading rate analysis revealed actual insulin contents 
of 0.09%, 0.69%, and 1.71% (w/w); the scaffolds were designated I0.1%, I0.7%, and 
I1.7% (Tab. 2).  
 
group insulin content (w/w) SD 
scaffold I 0.1% 0.09% 0.005% 
scaffold I 0.7% 0.69% 0.003% 
scaffold I 1.7% 1.71% 0.064% 
 
Tab. 2: Insulin content of the insulin-loaded scaffolds determined by two-phase extraction and HPLC 
quantification. Each group was determined in triplicate. 
 
Construct wet weight, size, and cell number 
The constructs generated with the insulin-loaded scaffolds dose-dependently increased in wet 
weight after three weeks of culture (Fig. 12A); the weights of the constructs with the highest 
insulin loading (I1.7%) increased 1.2-fold, compared to the control (I1.7%: 105mg vs. 
control: 87mg). In contrast, insulin applied in a high single dose (“burst”) did not result in 
increased weights, as compared to the control (Fig. 12A). For comparison, insulin 
exogenously applied over the whole cultivation period (I1.4) led to a 1.5-fold weight increase. 
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The weight measurements were well reflected by the size of the contructs (Fig. 11). With 
regard to cell content, no significant differences were measured between all groups. 
Glycosaminoglycans 
The insulin-loaded scaffolds resulted in a loading dose-dependent increase in the mass of 
glycosaminoglycans (GAG) (Fig. 12D). The I0.7% and I1.7% groups showed significant  
increases (1.4-fold for I0.7%, 1.7-fold for I1.7%) compared to the control (I0.7%: 2.4mg; 
I1.7%: 2.9mg vs. control: 1.7mg). The scaffolds of the groups with one high single insulin 
application (“burst”), I10µ and I200µ, performed significantly weaker compared to the 
scaffolds with highest insulin loading (I10µ:1.3mg; I200µ: 1.6mg vs. I1.7%: 2.0mg). Highest 
increase in GAG was observed after exogenous application of insulin over the whole culture 
period (I1.4), resulting in a 2.5-fold increase of GAG, as compared to the control.  
Similar differences between groups were also detected for GAG content expressed per cell 
and per wet weight, respectively (Fig. 12E, F). Also dose-dependent increases were observed  
for the differently loaded scaffolds, with 1.5-fold (Fig. 12E) and 1.4-fold (Fig. 12F) increase 
of the scaffolds with the highest loading compared to the control. Again, values of the “burst” 
groups (I10µ, I200µ) were considerably lower. 
Collagens 
Insulin-releasing scaffolds resulted in no significant increase in generated mass of collagen 
(Fig. 12G), compared to the control. A significant difference could be found between both 
insulin-loaded scaffolds I0.7%/I1.7% and the external burst group I10µ (I0.7%: 2.5mg; 
I1.7%: 2.7mg vs. I10µ: 2.0mg). The continuous external insulin application, I1.4, led to 1.4-
fold increase in collagen mass (I1.4: 4.3mg vs. control: 2.7mg). The collagen per cell (Fig. 
12E) and collagen per wet weight (Fig. 12F) fractions of all groups showed no significant 
differences to the control. 
Macroscopizc appearance and histology 
In the histological sections (Fig. 10), GAG distributions were represented by red areas of the 
safranin-O staining. The insulin-loaded scaffolds resulted in a loading dose-dependent 
increase in the area and strength of safranin-O staining (Fig. 10: Safranin-O staining of cross-
section of scaffolds after three weeks of cultivation, after formalin fixation and paraffin 
embedding.); the insulin-loaded scaffolds I0.7% and I1.7% clearly increased GAG area and 
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staining, as compared to the control, well reflecting the GAG quantification (compare Fig. 
12D-F). The burst release groups I10µ and I200µ showed distinctly less staining for GAG, as 
compared to the insulin-loaded scaffolds I0.7% and I1.7%, and similar staining as the control 
group (Fig. 3). The strongest staining was observed for the group receiving exogenous insulin 
over the whole cultivation period (I1.4) (Fig. 10), again well reflecting the quantification data 
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Fig. 10: Safranin-O staining of cross-section of scaffolds after three weeks of cultivation, after formalin fixation and paraffin 
embedding.  
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Fig. 11: Stereooptic photo of the cultivated scaffolds after 



















































 Fig. 12.: Data from cell culture experiments after three weeks of cultivation Data represents the average ± 
SD of four independent cartilaginous constructs. Statistically significant differences between the groups are 
denoted by symbol (°) (p<0.05) or asterisk (*) (p<0.01).
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 Fig. 12.: Data from cell culture experiments after three weeks of cultivation Data represents the average ± 
SD of four independent cartilaginous constructs. Statistically significant differences between the groups are 
denoted by symbol (°) (p<0.05) or asterisk (*) (p<0.01). 
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 Discussion 
In this chapter the suitability of recently developed macroporous PLGA scaffolds (Hacker, 
Biomaterials 2003) as a controlled release device was investigated in a 3-D cartilage 
engineering culture. The interconnectivity and pore size of 100-300µm, adjusted by the size 
of the chosen lipid microparticles, which were used as porogens, has been proven to be 
suitable for cell attachment and homogenous cell distribution in previous studies [24]. 
However, when used as release device for proteins, manufacturing processes of the scaffolds, 
storage and the release itself may compromise protein stability [58]. Thus, besides the 
determination of the release kinetics by standard assays such as HPLC or enzyme-linked 
immunosorbent assay, it is also paramount to check the bioactivity of the released protein in a 
relevant environment [43]. Here, insulin was used as a model protein, which we have 
previously demonstrated to be suitable to evaluate controlled release devices in the same 
insulin-sensitive 3-D cartilage engineering culture that was also employed in the presented 
study [18, 43].  
 
The produced scaffolds were loaded with bovine insulin in concentrations of 0.1%, 0.7%, and 
1.7% (Tab. 2). Prior to cell seeding, insufficiently embedded insulin crystals were washed out 
over 24h to prevent burst release effects. Additionally, in two control groups, single doses of 
exogenous insulin (10 and 200 µg/ml, respectively) were applied at the beginning of the 
culture period in order to simulate a potential burst release.  
 
Insulin-loaded scaffolds resulted in dose-dependent increases of wet weight, size, and GAG 
content of the generated cartilaginous constructs after three weeks of culture (Fig. 12A, D-F; 
Fig. 10). Especially the scaffolds with the highest loading resulted in significant increases of 
weight, size, and GAG content, as compared to control constructs receiving either no insulin 
or receiving a single exogenous insulin dose at the beginning of the culture period. The latter 
comparison implied that the effects of the insulin-releasing scaffolds could not be attributed to 
a burst, but rather a prolonged release. For all groups, differences in GAG content quantified 
by DMMB assay (Fig. 12D-F) were confirmed by histological analysis (Fig. 10).  
With regard to collagen content, all insulin-loaded scaffolds did not improve the constructs 
over control. Only insulin exogenously applied over the whole cultivation period resulted in 
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increased collagen content, it also led to the highest values for all other parameters measured. 
As the exogenously applied insulin concentration of 1.4 µg/ml was well above the 
concentration that was theoretically achievable with the scaffolds with the highest insulin 
loading, these results were to be expected. The observation that the insulin-loaded scaffolds 
increased construct weight and GAG content, but not collagen content may be attributed to 
low insulin release in the later period of the culture: In previous studies with several 
harvesting time points it was shown that, in contrast to early increases in GAG content, 
collagen increase mostly occurs at later stages, e.g., beginning from the third week of 
cultivation [18]. To validate this suggestion it becomes mandatory to analyze the released 
insulin in further studies.  
 
In literature recent approaches manufacturing macroporous scaffolds for controlled release of 
growth factors, mostly dealt with protein loaded microspheres which were entrapped within 
the polymeric scaffold (PLA/PLGA) during scaffolding process [67, 73-76]. This double 
wrapping of growth factors may lead to very low loading rates within the resulting scaffold. 
Another approach utilized biphasic emulsion technique to embed proteinic growth factors into 
PLA/PLGA scaffolds during scaffold molding [77]. The emulsion processes often include 
organic solvents likely to result in organic-water interfaces, which in turn are known as 
destabilizing factor for proteins [56]. Supercritical carbon dioxide (scCO2) was used in single-
phase gas foaming scaffolding process utilizing polymer material (PLA/PLGA) and protein 
[60, 61, 64, 78]. For improved pore forming NaCl crystals were embedded within gas foamed 
scaffolds. The following aqueous leaching process might lead to a loss of proteins. Other 
approaches dealt with protein loading techniques for the prefabricated scaffolds. One group 
used polymeric protein containing films, which coated a prefabricated scaffold with a protein-
containing polymeric emulsion on top [67, 73]. Another group loaded macroporous polymeric 
scaffolds with protein containing hydrogels [79]. These basic approaches seem to have 
promise, but need further research. Also different scaffold materials as e.g. chitosan were 
utilized, but they lack a FDA approval [62, 63, 80]. 
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In conclusion, in this study bovine insulin released from macroporous scaffolds improved 
cartilaginous constructs, specifically weight and GAG content. The observed effects were not 
caused by a single burst release, as the burst release controls did not increase weight and GAG 
content. Further analytics need to be performed to get a closer understanding of the release 
profile and the amounts of released insulin. However, already from this data it can be 
concluded that the embedded insulin was released over an extended period of time under 
retention of its bioactivity.  
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Introduction 
Articular cartilage shows only limited capacity for self repair. Large defects often develop as 
a point of origin of osteoarthritis in the synovial joint. So the treatment of cartilage defects 
still remains a challenge. Tissue engineering applications represent an important therapeutic 
option, especially for larger defects in the joint. The limited source of autologous harvestable 
cells represent one major limiting factor for engineering of cartilage substitutes. An approach 
to overcome this problem consists in the prior proliferation of harvested cells in a 2-D culture. 
Afterwards the expanded cells are seeded on a 3-D cell carrier and further cultivated. 
However, proliferation in 2-D culture commonly results in cell dedifferentiation rendering the 
cells less suitable for tissue engineering purposes [15]. One approach to improve engineered 
cartilage constructs is the application of growth factors, either during cell expansion or during 
tissue construct development. The aim of this study was to elucidate the potential of the 
protein growth and differentiation factor-5 (GDF-5) to improve tissue construct development 
either made from primary or from expanded chondrocytes.  
 
GDF-5 is a member of the bone morphogenetic protein (BMP) subfamily; BMPs in turn are 
members of the TGF-β superfamily and were originally identified as inducers of bone and 
cartilage formation in vivo. Homodimeric BMPs induce ligand-dependent type I and II 
receptor heterodimerization of transmembranic serine-threonine kinases [81, 82]. GDF-5, also 
known as cartilage-derived morphogenetic protein 1 (CDMP1), is a known partner in digit 
and limb formation [25-27] and is also found in the stage of precartilaginous mesenchymal 
condensation and throughout the cartilaginous cores of the developing long bones of bovine 
embryos [28]. It has also been postulated to be involved in the maintenance of normal 
cartilage and regenerative response in diseased tissue as it was found in the superficial layer 
of normal cartilage and throughout osteoarthritic cartilage [83].  
Chapter 5  Synergistic effects of GDF-5 and insulin 
- 59 - 
 
Within this study, the effects on development of engineered cartilage of either GDF-5 alone or 
in combination with bovine insulin were investigated. Insulin has previously been 
demonstrated to have strong anabolic effects on engineered cartilaginous constructs from 
primary cells similar to those of insulin-like growth factor-I (IGF-I) [18]. Specifically, in the 
experiments presented here, engineered cartilage constructs were assessed with regard to their 
histological appearance and extracellular matrix (ECM) composition, i.e., glycosaminoglycan 
and collagen content. The study demonstrates the synergistic effects of GDF-5 and insulin to 
improve cartilaginous cell-polymer constructs made from either primary or expanded 
(passage 2) chondrocytes.  
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Results 
Primary chondrocyte culture 
Wet weight and cell number 
Within 21 days of culture, GDF-5 at 0.1 µg/ml and 0.5µg/ml increased construct wet weight 
2.3-fold and 5.3-fold, respectively, as compared to control; no effect was observed at 0.01 
µg/ml (Fig. 13A). Insulin at the routinely used concentration of 2.5 µg/ml increased the wet 
weight 3-fold. Strikingly, in combination with insulin, even the low concentrations of GDF-5 
led to a strong increase in wet weight (5.7-fold for GDF-5 at 0.01 µg/ml and 7.5-fold for 
GDF-5 at 0.1 µg/ml) (Fig. 13A).  
The cell number per wet weight decreased by the supplementation with growth factors (Fig. 
13B). GDF-5 applied alone resulted in a slight dose-dependent decrease to 73 % and 67 % for 
GDF-5 at 0.1µg/ml and 0.5µg/ml, respectively. The addition of insulin, either alone or in 
combination with GDF-5 decreased the relative cell number to 60-53 %.  
Glycosaminoglycan and collagen content 
The glycosaminoglycan (GAG) content in the cartilaginous constructs from primary cells was 
strongly increased by the addition of supplemented proteins (Fig. 13C). The absolute amount 
of GAG was increased dose-dependently up to 9.9-fold in the presence of GFD-5 alone and 5-
fold in the presence of insulin alone; the combination of GFD-5 and insulin yielded an 
increase up to 12-fold compared to the control (Fig. 13C). For the GAG content per cell 
highest values were obtained for insulin, GDF-5 alone at the highest concentration, and the 
combinations (up to 3.1-fold increase) (Fig. 13D). The differential GAG content in the 
scaffolds was also confirmed histologically by safranin-O staining (data not shown), in which 
all all growth factor recieving groups showed a strong red staining for GAG. 
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The addition of proteins affected the amount of total collagen in a similar fashion as observed 
for GAG. Again, a strong dose-dependent increase was observed for GDF-5 and highest 
values were obtained for the combination of GDF-5 and insulin (5.2-fold increase) (Fig. 13E). 
The collagen content per cell was increased for all insulin-receiving groups; GDF-5 alone had 
no significant effect (Fig. 13F). Immunohistochemical analysis demonstrated a homogeneous 
anti-collagen II staining throughout the whole cross-section of all scaffolds, only at the edges 



































































































































Fig. 13:  Wet weight (A), cell number (B), GAG content (C-D), and collagen content (E-F) of cartilaginous constructs 
generated with primary chondrocytes after three weeks of culture. CTR: control; I2.5: insulin at 2.5µg/ml; G: GDF-5 
at 0.0.1, 0.1, or 0.5 µg/ml; G + I: GDF-5 at 0.01 or 0.1 µg/ml combined with insulin at 2.5 µg/ml. Data represents the 
average ± SD of four independent constructs. Statistically significant differences between the groups are denoted by 
symbol (°) (p<0.05) or asterisk (*) (p<0.01). 
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Passage 2 chondrocyte culture 
Macroscopic appearance, wet weight, and cell number  
Employing passage 2 chondrocytes, after a culture period of 21 days constructs of the control 
group were comparably small (approx. half of the diameter of the original scaffold (0.5 mm)) 
(Fig. 14) and had only about 16% of wet weight of primary chondrocyte control constructs 
(Fig. 15A, compare Fig. 13A). Whereas insulin increased the wet weight by 2.2-fold, GDF-5 
alone led to no significant increase in wet weight. However, in combination with insulin, 
GDF-5 increased the wet weight by 3.2-fold (GDF-5 at 0.01 µg/ml) and 4.8-fold (GDF-5 at 
0.1 µg/ml), respectively (Fig. 15A). The constructs of the latter group were the only ones that 
maintained the original scaffold size (Fig. 14).  
 
Fig. 14: Macroscopic appearance of cell-polymer constructs generated with passage 2 chondrocytes after three 
weeks of culture. .CTR: control; I2.5: insulin at 2.5µg/ml; G: GDF-5 at 0.0.1, 0.1, or 0.5 µg/ml; G + I: GDF-5 at 0.01 
or 0.1 µg/ml combined with insulin at 2.5 µg/ml. 
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The cell number per wet weight was not significantly affected by GDF-5 alone. It was 
decreased for all insulin receiving groups, as compared to the control, with lowest values for 
the combinations of insulin and GDF-5 (decrease down to 32%) (Fig. 15B). 
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 Glycosaminoglycan and collagen content 
The administration of a single protein did not cause a significant difference in GAG content. 
However, both combinations of GDF-5 and insulin resulted in significant increases in 





























































































































 Fig. 15: Wet weight (A), cell number (B), GAG content (C-D), and collagen content (E-F) of cell-polymer constructs 
generated with passage 2 chondrocytes after three weeks of culture. CTR: control; I2.5: insulin at 2.5µg/ml; G: GDF-5 
at 0.0.1, 0.1, or 0.5 µg/ml; G + I: GDF-5 at 0.01 or 0.1 µg/ml combined with insulin at 2.5 µg/ml. Data represents the 
average ± SD of four independent constructs. .Statistically significant differences between the groups are denoted by 
symbol (°) (p<0.05) or asterisk (*) (p<0.01).  
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The collagen content was also not significantly affected by GDF-5 alone. Insulin alone 
increased the collagen content, but highest values were again obtained for the combinations of 
GDF-5 and insulin, with increases in absolute amount of collagen up to 5.3-fold and in 
collagen per cell up to 3.8-fold (Fig. 15E, F). 
Histology 
The control group exhibited small constructs with large areas of cells with a fibroblastic 
phenotype (stained blue) and a small core stained red for GAG with safranin-O (Fig. 16). The 
addition of insulin resulted in larger constructs, but still with large blue stained areas 
containing fibroblastic cells and a core with only weak GAG staining. Supplementation of 
GDF-5 alone resulted in an enhanced staining for GAG in the inner region of the construct, as 
compared to the control and insulin group; the blue stained areas were reduced to the outer 
regions of the scaffolds. The combination of GDF-5 and insulin resulted in scaffolds with an 
even stronger staining for GAG. In the combination receiving GDF-5 at 0.1 µg/ml, GAG was 
distributed throughout the constructs; small blue stained areas with fibroblastic cells could 
only be found on the edge of the constructs (Fig. 16).  







ctr G 0.01 
G 0.1 G 0.5 
Fig. 16: Glycosaminoglycan (GAG) distribution in cross-sections of cell-polymer constructs generated with 
passage 2 chondrocytes. GAG was stained red with safranin-O (appears dark gray in black & white print). . 
CTR: control; I2.5: insulin at 2.5µg/ml; G: GDF-5 at 0.0.1, 0.1, or 0.5 g/ml; G + I: GDF-5 at 0.01 or 0.1 µg/ml 
combined with insulin at 2.5 µg/ml.
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Fig. 16: Glycosaminoglycan (GAG) distribution in cross-sections of cell-polymer constructs generated with 
passage 2 chondrocytes. GAG was stained red with safranin-O (appears dark gray in black & white print). . 
CTR: control; I2.5: insulin at 2.5µg/ml; G: GDF-5 at 0.0.1, 0.1, or 0.5 g/ml; G + I: GDF-5 at 0.01 or 0.1 µg/ml 
combined with insulin at 2.5 µg/ml. 
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Fig. 17: Collagen type I (A) and collagen type II (B) 
distributions in cross-sections of cell-polymer  
constructs generated with passage 2 chondrocytes. 
Collagen type I and II were immunohistochemically 
labelled with anti-collagen type I and anti-collagen 
type II antibody, respectively, and stained brown with 
DAB (appears dark gray in the black & white print). 
CTR: control; I2.5: insulin at 2.5µg/ml; G: GDF-5 at 
0.0.1, 0.1, or 0.5 µg/ml; G + I: GDF-5 at 0.01 or 0.1 
µg/ml combined with insulin at 2.5 µg/ml.
 - 68 - 
Chapter 5  Synergistic effects of GDF-5 and insulin 
B  
  
ctr G 0.01 
  
G 0.1 G 0.05 
 
 
I 2.5 G 0.01+I 
 
G 0.1+I 
Fig. 17: Collagen type I (A) and collagen type II (B) 
distributions in cross-sections of cell-polymer  
constructs generated with passage 2 chondrocytes. 
Collagen type I and II were immunohistochemically 
labelled with anti-collagen type I and anti-collagen 
type II antibody, respectively, and stained brown with 
DAB (appears dark gray in the black & white print). 
CTR: control; I2.5: insulin at 2.5µg/ml; G: GDF-5 at 
0.0.1, 0.1, or 0.5 µg/ml; G + I: GDF-5 at 0.01 or 0.1 
µg/ml combined with insulin at 2.5 µg/ml. 
- 69 - 
Synergistic effects of GDF-5 and insulin  Chapter 5 
 - 70 - 
Immunohistochemical staining 
Staining for collagen type I was detected throughout the control constructs; insulin alone led 
to even more intensive staining (Fig. 17A). GDF-5 alone elicited a biphasic response: At low 
concentration of 0.01 µg/ml, a collagen type I staining similar as in the control constructs was 
observed; at 0.1 µg/ml GDF-5, a reduction of collagen type I in large areas of the core of the 
construct was observed; in contrast, at 0.5 µg/ml GDF-5, the strongest staining for collagen 
type I of all groups was detected. Strikingly, the combination of GDF-5 and insulin led to a 
distinct reduction of collagen type I staining; especially in the combination GDF-5/insulin 
0.1/2.5 µg/ml, there was no collagen I detectable throughout the construct except for a thin 
area at the edge (Fig. 17A). Decreased collagen I expression for GDF-5 at 0.1 µg/ml and for 
the GDF-5/insulin combinations, and increased expression for GDF-5 at 0.5 µg/ml were 
confirmed by RT-PCR analysis (data not shown).  
Collagen type II (Fig. 17B) could not be detected in control constructs and in constructs 
receiving either insulin or GDF-5 alone. However, the combination GDF-5/insulin at 0.01/2.5 
µg/ml showed collagen type II staining in small areas, and at 0.1/2.5 µg/ml the combination 
resulted in well-distributed staining in large areas of the constructs. As compared to the 
control group, an increased collagen II expression was detected using RT-PCR for all groups 
except for GDF-5 at 0.5 µg/ml, for which a decrease was observed (data not shown).  
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Discussion 
The use of in vitro expanded chondrocytes is still one of the major obstacles in the generation 
of engineered cartilaginous constructs. In order to improve constructs made from passaged 
chondrocytes, different approaches have employed various growth factors either during the 
expansion phase or during construct development [84-88]. To the best of our knowledge, this 
study for the first time investigated the effects of growth and development factor-5 during in 
vitro construct culture, either alone or in combination with insulin, on the quality of 
cartilaginous constructs made from primary or expanded chondrocytes. With primary 
chondrocytes, GDF-5 elicited similar improving responses as compared to insulin, which has 
been previously established as beneficial in cartilage engineering [18, 41, 43]. However, with 
passage 2 chondrocytes the use of neither insulin nor GDF-5 alone led to convincing 
cartilaginous constructs. In contrast, the combination of GDF-5 and insulin strongly improved 
the macroscopic and histological appearance as well as extracellular matrix composition of 
the engineered cartilage. 
 
From previous reports in the literature, GDF-5 is well known for its role in early 
chondrogenesis. Apparently GDF-5 plays an essential role in the embryonic chondrogenesis 
and limb formation, however the function of GDF-5 in adult cartilage is still to be elucidated 
[82, 89]. Nevertheless, GDF-5 remains an interesting candidate molecule for cartilage 
engineering applications, as it was found to be expressed in adult bovine and human cartilage 
in both normal and osteoarthritic tissue [83]. In a rabbit cartilage defect model (trochlear 
groove in adult rabbits), the application of GDF-5 adsorbed on collagen-I sponges improved 
the histological appearance of the repair tissue at 4 and 8 weeks after surgery, but after 24 
weeks no beneficial effect of the growth factor was detectable, as compared to the control 
[90]. Furthermore, the use of GDF-5 has been suggested in the healing of Achilles tendon 
defects [91, 92]. 
 
Within this study, GDF-5 has been evaluated with regard to its ability to improve engineered 
cartilage constructs made from bovine juvenile chondrocytes in vitro. On primary 
chondrocytes, GDF-5 elicited strong dose-dependent anabolic effects which were reflected by 
total wet weight and the extracellular matrix content of the treated scaffolds, i.e., both GAG 
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and collagen content (distinct effects already at 0.1 µg/ml GDF-5 and up to 9.9-fold increase 
in mass of GAG (Fig. 13C) and up to 4.2-fold increase in mass of collagen (Fig. 13E) for 
GDF-5 at 0.5µg/ml). Previously, in a cartilage defect model system with trypsin-treated 
bovine cartilage, at a concentration of GDF-5 of 0.1 µg/ml also an increase in proteoglycan 
synthesis was detected by increased 35S-sulfate incorporation at day 5 [83]. Intervertebral disk 
cells isolated from GDF-5 deficient mice and embedded in alginate beads responded to GDF-
5 treatment in concentrations up to 0.1 µg/ml with upregulated expression of type II collagen 
and aggrecan genes in a dose-dependent manner [93].  
 
In the present study, strikingly, when combining GDF-5 at concentrations of 0.01 and 0.1 
µg/ml with insulin (2.5 µg/ml), wet weight as well as GAG and collagen amounts were 
strongly increased in a synergistic fashion as compared to either factor alone at the same 
concentration. This was especially remarkable for GDF-5 at 0.01 µg/ml, as at this 
concentration GDF-5 alone resulted in no significant increase, neither for total weight nor for 
the ECM fractions; however, combined with insulin, GDF-5 at this concentration increased 
the weight and ECM fractions compared to those achieved with insulin alone for both 1.9-fold  
(Fig. 13A,C,E). The ECM content expressed per cell was not affected in the constructs 
receiving the combinations as compared to those receiving insulin alone (Fig. 13,F), with 
similar cell numbers per weight for the combinations and insulin alone (Fig. 13B). Thus, 
combining GDF-5 with insulin led to distinctly larger constructs than insulin alone, with 
similar relative cell numbers and cells that were equally active in producing ECM. 
 
Constructs generated with passage 2 cells, in general, were a lot smaller and lighter than their 
primary cell counterparts; histological analysis of control constructs revealed a 
dedifferentiated phenotype with a fibroblastic appearance, correlating staining for collagen 
type I throughout the construct, and no staining for the cartilage-specific collagen type II (Fig. 
16, Fig. 17). 
 
GDF-5 alone did not significantly affect the wet weight and the amounts of GAG and total 
collagen (Fig. 15A, C, E). However, GDF-5 elicited a biphasic response with regard to 
collagen type I expression: Whereas staining for collagen type I was distinctly reduced in 
large parts of the construct at 0.1 µg/ml, it was increased at 0.5 µg/ml, as compared to control 
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constructs (Fig. 17). The reason for this biphasic response remains to be elucidated in future 
studies. Previously, it has been reported that GDF-5 supplementation in concentration of 
500ng/ml led to a down-regulation of collagen type I expression in human mesenchymal stem 
cells [94]. Also, GDF-5 stimulated the ECM response of fetal rat calvarial cells towards the 
chondrogenic phenotype [95]. 
 
In our study, for passage 2 cells also striking advantageous effects were observed when 
combining GDF-5 with insulin, which were even more pronounced than for primary 
chondrocytes. Insulin alone increased the weight and the collagen fraction (Fig. 15A,E), 
however, no collagen type II staining was detected and collagen type I staining was clearly 
increased, as compared to control (Fig. 17). The combination of GDF-5 (at 0.01 and 0.1 
µg/ml) and insulin (2.5 µg/ml) yielded increases of weight and GAG and collagen amounts 
which were distinctly higher than those of insulin alone (Fig. 15A,C,E). Moreover, in the 
constructs receiving the combinations, also the GAG and collagen contents expressed per cell 
were distinctly increased, as compared to control and insulin-receiving constructs, which 
again was especially remarkable as GDF-5 alone resulted in no significant increases at all 
(Fig. 15D,F). Even more important, the combination GFD-5/insulin led to a clear shift in 
collagen subtype expression towards that of a more cartilaginous phenotype: Employing 
GDF-5 at 0.1 µg/ml yielded a staining for collagen II throughout the construct and a reduction 
of collagen I staining to only a thin layer at the edge of the construct. Taken together, whereas 
neither factor alone was able to overcome the dedifferentiation resulting from chondrocyte 
expansion, the combination of GDF-5 and insulin led to cartilaginous constructs with more 
actively ECM producing cells and a distinctly improved collagen subtype content.  
 
In conclusion, in the presented study, GDF-5 was demonstrated to be a useful protein in 
cartilage engineering in vitro. Especially in combination with insulin, GDF-5 appears to 
enable the redifferentiation of expanded chondrocytes and the concurrent generation of 
relevant cartilaginous constructs. As an alternative approach, a recent study has used growth 
factor supplementation during chondrocyte expansion in order to improve redifferentiation in 
a 3-D environment [85]. In analogy to this approach, it may be also worthwhile investigating 
the effects of GDF-5 on the quality of cartilaginous constructs when applied during 
chondrocyte expansion. With regard to the synergistic effects of GFD-5 and insulin observed 
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in the present study, further research is required to elucidate the mechanism on the molecular 
level. The fact that GDF-5 was demonstrated to decisively modulate the response to another 
cartilage-effectice protein contributes to the emerging picture of the role GDF-5 apparently 
plays in chondrogenesis and cartilage physiology. 
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Introduction 
Cartilage tissues have been proven to be steroid hormone-sensitive. Articular cartilage was 
found to be an estrogen-sensitive tissue [96]. Further evidence on the influence of steroid 
hormones on the development of cartilage came from menopausal women, where 
supplementation of estrogen resulted in an improved cartilage matrix, higher mobility and 
reduced pain within the synovial joint [97-99]. In rat cartilage, receptors specific for 17-β-
estradiol and testosterone could be found [100] and estrogen receptors were further specified 
for human articular cartilage. Two different estrogen receptor (ER) in human chondrocytes 
could be detected, ER-α and ER-β [101] . 
Estrogens and androgens in peripheral cells are connected with each other in complex 
pathways under inclusion of androgen precursors, such as dehydroepiandrosterone (DHEA). 
DHEA, a 19-carbon steroid hormone, is a member of the adrenal androgen family, released 
from the adrenal gland. From the findings of its decreasing concentration with age in plasma, 
it is known as an “antidote from aging” [102]. DHEA was found to reduce IL-1β-induced 
syntheses of catabolic enzymes, such as MMP-1 and -3, and to up-regulate inhibitors of 
MMPs, such as TIMP-1 gene expressions [103]. It was also found to be capable of 
suppressing interleukin 6 (IL-6) secretion in man in vitro [104]. Other studies demonstrated 
the suppressing influence of DHEA and testosterone on the secretion of IL-1β, IL-6 and 
tumor necrosis factor (TNF) [104, 105]. DHEA as one of the major androgen precursors can 
be enzymatically converted to testosterone by consecutive reaction with 17β-hydroxysteroid 
dehydrogenase and 3β-hydroxysteroid dehydrogenase (alternatively in reverse order) [106]. A 
conversion to estrogens is possible for testosterone by aromatase to 17-β-estradiol, and for 
DHEA by 3β-hydroxysteroid dehydrogenase via androstenedione, which is in turn converted 
by aromatase to estrone. Estrone and 17-β-estradiol can be converted into each other by 17β-
hydroxysteroid dehydrogenase [106].  
In this study, preliminary experiments were conducted in order to investigate the effects of 
steroid hormones on tissue engineering of cartilage in our bovine cell culture model. 
Hormones were tested with regard to their effects on primary and expanded chondrocytes. For 
primary chondrocytes, hormones were additionally evaluated under different oxygen partial 
pressures (21% and 5%).  
Chapter 6  Effects of steroid hormones 
- 79 - 
Results 
First study – 2 and 4 weeks primary culture 
In the first study with primary chondrocytes and two harvesting points of time after two and 
four weeks, the scaffolds generally increased in wet weight and especially collagen content 
after four weeks of cultivation, compared to the results from the two weeks groups (Fig. 18).  
Wet weight 
For control constructs, a 1.4-fold increase in wet weight (Fig. 18A) was found after 4 weeks 
as compared to after two weeks (48.3mg vs. 68.7mg for control groups after 2 and 4 weeks). 
Similar increases were observed for the testosterone 10-7mol/l (T1) and the DHEA 10-7mol/l 
(D1) groups; all other groups showed lower increases. Within the two weeks groups no 
differences could be found. 
Within the 2 and 4 weeks groups, no significant differences in wet weight could be found.  
Glycosaminoglycans 
Between the 2 and 4 weeks groups no definite trends were obvious and detectable. Only for 
the controls a distinct 1.6-fold increase (Fig. 18D) in the mass of GAG (1.6mg vs. 2.5mg 
GAG for 2 vs. 4 weeks group) and a 1.7-fold increase for the GAG per cell fraction (Fig. 18E) 
(152pg vs. 264pg for 2 vs. 4 weeks group) could be detected, but no difference in the GAG 
per wet weight fraction (Fig. 18F) (3.4% vs. 3.6% for 2 vs. 4 weeks group). 
Within the two weeks groups, a significant increase in GAG per wet weight fraction for 
estrogen 10-9mol/l (E-09) (3.4% vs. 5.0% for control vs. estrogen 10-9) (Fig. 18F) was 
demonstrated. Further a tendency to increased GAG amount for estrogen 10-10mol/l (E-10) 
and 10-9mol/l (E-09) groups were detectable (1.6mg (control) vs. 2.6mg (estrogen both 10-
10mol/l (E-10) and 10-9mol/l (E-09)) (Fig. 18D). Increased GAG per cell fraction for estrogen 
10-9mol/l (E-09) (151.7pg vs. 261.3pg for control vs. estrogen 10-9mol/l (E-09)) (Fig. 18E). 
The four weeks groups showed no significant differences in the GAG content. 





































































































































 Fig. 18: Data from primary chondrocyte constructs after 2 and 4 weeks of cultivation. All experiments were 
performed with two independent constructs per group. Group abbreviations: testosterone (T): T-09: 10-
9mol/l, T-08: 10-8mol/l, T-07: 10-7mol/l; 17β-estradiol (E): E-11: 10-11mol/l, E-10: 10-10mol/l, E-09: 10-
9mol/l; dehydroepiandrosterone (DHEA) (D): D-08: 10-8mol/l, D3-08: 3·10-8mol/l, D-07: 10-7mol/l.
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 Fig. 18: Data from primary chondrocyte constructs after 2 and 4 weeks of cultivation. All experiments were 
performed with two independent constructs per group. Group abbreviations: testosterone (T): T-09: 10-
9mol/l, T-08: 10-8mol/l, T-07: 10-7mol/l; 17β-estradiol (E): E-11: 10-11mol/l, E-10: 10-10mol/l, E-09: 10-9mol/l; 
dehydroepiandrosterone (DHEA) (D): D-08: 10-8mol/l, D3-08: 3·10-8mol/l, D-07: 10-7mol/l. 
Collagens 
The four weeks groups resulted in tremendously higher collagen mass, collagen per cell and 
collagen per wet weight fraction, as compared to the two weeks groups.  
For the two weeks groups no significant increase in collagen mass or collagen fraction could 
be found. A tendency to increased collagen weight could be found for testosterone 10-8mol/l 
(T-08) (0.86mg vs. 1.11mg for control vs. testosterone 10-9mol/l) with a 1.3-fold increase and 
estrogen 10-9mol/l (E-09) (0.86mg vs. 1.23mg for control vs. estrogen 10-9mol/l) with a 1.4-
fold increase. The same groups showed increase in the GAG per cell (79.4pg for control, 
118.4pg for testosterone 10-9mol/l, 123.8pg for estrogen 10-9mol/l) and in the GAG per wet 
weight fractions (1.8% for control, 2.3% for testosterone 10-9mol/l, 2.3% for estrogen 10-
9mol/l). 
 
Within the four weeks groups, significant increases in collagen per wet weight for estrogen 
10-10mol/l (E-10) and 10-9mol/l (E-09) groups (3.2% vs. 4.0%/4.3% for control vs. estrogen  
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0.1/1) (Fig. 18I) were detected. Further tendencies of an increase in collagen per cell fraction 























































































































 Fig. 19: Data from primary chondrocyte constructs after 3 weeks of cultivation under regular (21% O2) and 
low (5% O2) oxygen partial pressure. All experiments were performed with two independent constructs per 
group. Group abbreviations: testosterone (T): T-09: 10-9mol/l, T-08: 10-8mol/l, T-07: 10-7mol/l; 17β-
estradiol (E): E-11: 10-11mol/l, E-10: 10-10mol/l, E-09: 10-9mol/l; dehydroepiandrosterone (DHEA) (D): D-
08: 10-8mol/l, D3-08: 3·10-8mol/l, D-07: 10-7mol/l.
 - 82 - 
Chapter 6  Effects of steroid hormones 
































































 Fig. 19: Data from primary chondrocyte constructs after 3 weeks of cultivation under regular (21% O2) and 
low (5% O2) oxygen partial pressure. All experiments were performed with two independent constructs per 
group. Group abbreviations: testosterone (T): T-09: 10-9mol/l, T-08: 10-8mol/l, T-07: 10-7mol/l; 17β-estradiol 
(E): E-11: 10-11mol/l, E-10: 10-10mol/l, E-09: 10-9mol/l; dehydroepiandrosterone (DHEA) (D): D-08: 10-8mol/l, 
D3-08: 3·10-8mol/l, D-07: 10-7mol/l. 
 
Second study – differential oxygen partial pressure (three weeks)  
Wet weight 
As a general tendency, low oxygen conditions resulted in increased wet weight (Fig. 19A) for 
all groups. At 21% oxygen, constructs of the estrogen 10-9mol/l (E-09) group increased in wet 
weight 1.7-fold, compared to the control (21.3mg vs. 35.2mg for control vs. estrogen 10-
9mol/l). At 5% oxygen, a 1.2-fold increase of wet weight were detected for testosterone 10-
7mol/l (T-07), estrogen 10-10mol/l and 10-9mol/l (E-10, E-09) as well as for DHEA 3·10-8mol/l 
(D3-08) and 10-7mol/l (D-07).  
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Glycosaminoglycans 
At 21% oxygen, constructs of the estrogen 10-9mol/l (E-09) group increased 2-fold in mass of 
GAG (Fig. 19D), compared to the control (0.9mg vs. 1.7mg for control vs. estrogen 10-
9mol/l). At 5% oxygen, testosterone 10-7mol/l (T-07) increased the mass of GAG 1.5-fold, 
estrogen 10-9mol/l (E-09) 1.4-fold, and DHEA 10-7mol/l (D-07) 1.4-fold (control: 1.4mg vs. 
T-07: 2.2mg, E-09: 2.0mg, D-07: 2.1mg). Same trends were also detectable for the GAG per 
cell fraction (Fig. 19E): Under high oxygen partial pressure, constructs of the estrogen 10-
9mol/l (E-09) group increased 1.3-fold (163pg vs. 220pg for control vs. E-09, 21% O2). Under 
low oxygen pressure, the testosterone 10-7mol/l (T-07) group increased in GAG per cell 1.6-
fold, estrogen 10-9mol/l (E-09) increased 1.4-fold and DHEA 10-7mol/l (D-07) 1.3-fold 
(control: 177pg vs. T-07: 277pg, E-09: 243pg and D-07: 231pg, 5% O2). 
Collagens 
Under high oxygen partial pressure, mass of collagen was especially increased for estrogen 
10-9mol/l (E-09) (3-fold, 0.4mg vs. 1.2mg for control vs. E-09) (Fig. 19G). Similar results 
were observed for the collagen per cell (Fig. 19H) and the collagen per weight fraction (Fig. 
2I), for which estrogen 10-9mol/l (E1) yielded the largest increases (1.7-fold and 1.7-fold), as 
compared to the control. . 
All low oxygen groups increased mass of collagen compared to the related high oxygen 
group. Within low oxygen groups, a 1.3-fold increase in mass of collagen (Fig. 19G) could be 
detected for estrogen 10-9mol/l (E1) and a 1.3-fold decrease for testosterone 10-8mol/l (T0.1), 
both compared to the control (control: 1.4mg vs. estrogen 1: 1.8mg and testosterone 0.1: 
1.1mg). 
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Third study - Expanded chondrocytes (three weeks) 
Wet weight 
The addition of steroid hormones had no influence on the resulting wet weight (Fig. 20A) of 
the constructs after a cultivation period of 3 weeks. 
Glycosaminoglycans 
A tendency to decreasing mass of GAG (Fig. 20D), decreasing GAG per cell (Fig. 20E) and 





















































































































































 Fig. 20: Data from expanded chondrocytes constructs after 3 weeks of cultivation with 21% oxygen partial pressure. All 
experiments were performed with two independent constructs per group. Group abbreviations: testosterone (T): T-09: 
10-9mol/l, T-08: 10-8mol/l, T-07: 10-7mol/l; 17β-estradiol (E): E-11: 10-11mol/l, E-10: 10-10mol/l, E-09: 10-9mol/l; 
dehydroepiandrosterone (DHEA) (D): D-08: 10-8mol/l, D3-08: 3·10-8mol/l, D-07: 10-7mol/l. 
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Collagens 
Testosterone 10-7mol/l and DHEA 10-7mol/l increased mass of collagen (Fig. 20G) by 1.8-
fold and 2-fold, respectively (0.17mg for control, 0.3mg for testosterone 1, 0.34mg for DHEA 
10-7mol/l). For the collagen per wet weight fraction (Fig. 20I), the same trends were observed: 
Collagen per wet weight increased 2-fold for testosterone 10-7mol/l and DHEA 10-7mol/l, 
both compared to the control (2% for control vs. 4% for both testosterone 10-7mol/l and  
DHEA 10-7mol/l).  
Discussion  
In this study, the effects of steroid hormones on tissue engineered cartilage were investigated 
in preliminary experiments. In contrast to the previous chapters, the effects of steroid 
hormones on extracellular matrix development and increase of wet weight were generally 
small and remained distinctly behind the anabolic efficacy of protein factors like insulin and 
GDF-5. In the first study between the two and four weeks group increases in wet weight (Fig. 
18A) and collagen (Fig. 18G-I) were detectable. After 2 weeks, increases in GAG (Fig. 18D-
F) were detectable for estrogen in concentrations of 10-10mol/l and 10-9mol/l.  
 
Surprisingly, these increases were not sustained in the 4 weeks constructs, which showed 
similar or weaker GAG content (Fig. 18D-F). The collagen content of all constructs distinctly 
increased between 2 and 4 weeks of culture (Fig. 18G-I). Estrogen 10-9mol/l resulted in higher 
collagen content after 4 weeks, as compared to the control. In the second study, the responses 
of extracellular matrix development under the high oxygen culture conditions (21% O2) were 
comparable to those of the first study after 4 weeks of cultivation. Increases in GAG (Fig. 
19D-F) and collagen (Fig. 19G-I) content could be detected for the estrogen 10-9mol/l group.  
 
The response of extracellular matrix development to the steroid hormones changed with low 
oxygen culture conditions (5% O2). Increases in GAG (Fig. 19D-F) content in addition to 
estrogen 10-9mol/l could also be found for lower concentrated estrogen 10-10mol/l, 
testosterone 10-7mol/l, and DHEA 10-7mol/l. For collagen mass (Fig. 19G), in the low oxygen 
groups (5% O2), an increase was detected for estrogen 10-9mol/l, as well as a decrease for 
testosterone 10-8mol/l.  
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One side aspect of this chapter dealt with the effects of a combination of insulin and estrogen. 
In literature interesting effects were described of this combination (insulin and estrogen) on 
primary bovine cells from adult cows cultivated in monolayer culture under low oxygen (5% 
O2) partial pressure.  
 
Besides the insulin dose-dependent increase of proline incorporation, a suppression of 
anabolic insulin effects on proline incorporation by estradiol administration was reported 
[107]. These findings could not be confirmed in our cell culture model, as collagen contents 
(data not shown) of constructs receiving a combination of estrogen and insulin were not 
significantly different to those constructs receiving solely insulin. The postulated antagonism 
of estrogen on the anabolic effect of insulin on the proline incorporation and collagen 
production could not be found in our 3-D cell culture model. The differences of these findings 
may be attributed to a 100-fold higher estrogen concentration used in our study and/or to the 
3-D environment in contrast to the 2-D cell culture. In the third study, the effects of steroid 
hormones on constructs generated with expanded (passage 2) bovine chondrocytes were 
investigated. The influence of steroid hormones on wet weight (Fig. 20A) and GAG 
distribution (Fig. 20D-F) were only marginal. Interesting differences were found for collagen 
content (Fig. 20G-I): Testosterone 10-7mol/l and DHEA 10-7mol/l supplementation resulted in 
increased collagen contents, in contrast to the results from primary chondrocytes (which were 
originally from the same donor calf), for which only estrogen influenced the collagen content 
of the extracellular matrix. 
 
Articular cartilage acts as a steroid hormone-sensitive tissue. Intensive research was already 
done for the role of estrogens and androgens and other steroids on growth plate cartilage and 
longitudinal bone growth, which was recently reviewed [29-31]. For tissue engineered 
cartilage only little is known about the role of steroid hormones on the development of the 
constructs. From the results of this study, as of yet no definite recommendation can be made 
for the application of steroid hormones in vitro cartilage engineering.  
 
Further research needs to be conducted to get a more comprehensive view of the role of 
steroid hormones in growing engineered tissues. In future studies, attention should be paid to 
the selected concentrations of hormones, to find optimum concentrations with regard to a 
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potential biphasic dose response, as it was shown for estrogen elsewhere [108]. Furthermore, 
also the gender of the donor cells may be taken into consideration [31].  
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Introduction 
Articular cartilage is a blood vessel free tissue. So the supply of the cartilage cells with 
oxygen and other essential nutrients mostly occurs via diffusion from the synovial fluid or via 
“forced” convection by mechanical compression of the cartilage matrix. In this chapter we 
will focus on the effects of oxygen on the development of engineered cartilage tissue. Oxygen 
is required for cellular survival. It is known for its central role in the mitochondrial respiratory 
chain and also for its signalling function in regulating cell metabolism and response [109]. 
Furthermore oxygen has shown to influence the development of cells and tissues, including 
cartilage formation. However, the specific role of oxygen in these processes remains still 
unclear and the data reported is controversial [109].  
 
The regular oxygen tension in the synovial fluid is about 7% partial oxygen pressure, thus, it 
is lower compared to 12% oxygen in the arterial blood and vascularised tissue [110]. In vitro 
measurements within bovine tissue engineered constructs and native articular bovine cartilage 
showed a tendency to lower oxygen concentration for the tissue engineered constructs, 
compared to the native tissue, i.e., on the edge as well as in the centre of the constructs. Also 
an oxygen gradient was detected within the tissue engineered constructs from the edge to the 
near anoxic core [111]. The role of oxygen within developing tissues, both in embryonic 
tissues and engineered tissues remains unclear. It can be postulated, that oxygen plays an 
important role for those developing tissues, as oxygen was found as a mediator of 
developmental processes in cartilage formation [109]. Also for tissue engineering purposes 
further research on the effects of oxygen is mandatory, as it may also influence the 
redifferentiation of dedifferentiated cells and modulate the effect of growth factors on the 
targeted cells.  
 
The cell response of bovine chondrocytes to IL-1β was influenced by different oxygen partial 
pressures [112]. Furthermore, the collagen II deposition from dedifferentiated cartilage cells 
in alginate was also influenced by oxygen partial pressure [113, 114]. In Tab. 3, studies on 
cartilage and the influence of oxygen found in literature are summarized. All these data came 
from 2-D or alginate beads cell culture.  
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To the best of our knowledge, in this chapter we present the first data on the influence of 
oxygen partial pressure (21% vs. 5%) on a complex 3-D cartilage tissue engineering culture; 
this includes the effects on primary and expanded chondrocytes as well as the modulation of 
the effects of the growth factors insulin and growth and development factor-5 (GDF-5). 
 
 Species Type of culture, 
culture periode 
Low vs high oxygen 
tension 
Effect on ECM Reference 
Bovine AC in alginate 5%/20% Coll II ↑ 
Proteoglycan↑ 
[113] 
Bovine AC in alginate, 7d <0.1%/20% mRNA↓↓  
Lactat ↓ 
[110] 
Bovine AC in alginate, 7d <0.1%/20% mRNA Coll II↓ 
mRNA TIMP-1↑ 
[6] 
Bovine AC monolayers 5%/20% Coll II ↑ 
Coll IX ↑ 
Coll I ↓ 
Proliferation ↑ 
[115] 
Bovine Alginate and collagen I/Ill 
membrane cultures with AC 
5%/20% Ratio of protein and 
mRNA Coll II/Coll I ↑ 
[114] 
Bovine Articular cartilage explants 
4.5h 
0%/21% Sulfage incorporation ↓ [116] 
[117] 
Bovine PGA scaffold, 35d w/o gas exchange/20% GAG↓ 
Collagen↓ 
[118] 
Bovine AC in porous polylactic acid 
constructs 
5%/20% GAG ↑ 
Collagen +/- 
[119] 
Bovine Articular cartilage explants, 7d 6%/24% Sulfate incorporation ↓ [120] 
Primary 
Human OA AC on collagen I/III 
membranes 
5%/20% Proline and sulfate 
incorporation ↑ 
[121] 
Bovine Cells in alginate 5%/20% Coll II ↑ 
Coll IX ↑ 
Coll I ↓ 
[113] 
Bovine AC on collagen I/III membranes 5%/20% Coll II ↑ [114] 
Bovine AC in alginate 5%/20% mRNA Coll II ↑ 
mRNA aggrecan ↑ 
[122] 
Human Nasal cells in pellet culture 5%/20% 
1%/20% 
GAG ↑ 
Coll II ↑ 
GAG ↑↑ 




Human AC in alginate 5%/20% mRNA Coll II ↑ 
mRNA aggrecan ↑ 
[124] 
 
Tab. 3: Data from literature on the influence of low oxygen tension on matrix synthesis of primary and 
dedifferentiated articular chondrocytes (AC) taken from [125] and completed by the author. 
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Results 
Due to the numerous plots presented in this chapter, only the major differences can be 
presented and discussed in the Results and in the Discussion section. All the experiments 
were performed in quadruplicate, i.e., four independent scaffolds were cultured per group. 
Wet weight and cell number 
Primary chondrocytes 
For the primary chondrocytes (Fig. 18A) a tendency to increasing wet weights with reduced 
oxygen partial pressure was found for the control (47.3/68.5mg : 21%/5% O2) and all single 
growth factor groups (insulin 2.5µg/ml: 140.5/204.6mg; GDF-5 0.1µg/ml: 106.7/148.7mg for 
21%/5% O2). The combination of GDF-5 and insulin resulted in a tendency to lower wet 
weights for 5% oxygen partial pressure (GDF-5/insulin 0.1/2.5µg/ml: 352.0/291.8mg. for 
21%/5% O2). For the cell numbers per wet weight (Fig. 18C) no significant differences 
between 21%/5% O2 groups could be found. All insulin-receiving groups had a tendency to 
decrease cell number per wet weight. 
Expanded chondrocytes 
The constructs generated with expanded chondrocytes exhibited up to 8-fold lower wet 
weight (Fig. 22A), than constructs made from primary chondrocytes (up to 43.5mg for 
passage 2 vs. 352.0mg for primary chondrocytes). Anabolic effects were detected for all 
insulin-receiving groups. The addition of GDF-5 only resulted in no significant increase in 
wet weight (control: 7.6/8.6mg, GDF-5 0.1µg/ml: 10.9/10.7mg for 21%/5% O2). The 
combination of GDF-5/insulin produced a dose-dependent increase in wet weight (GDF-
5/insulin 0.01/2.5µg/ml vs. 0.1/2.5µg/ml: 24.0 vs. 36.6mg for 21% O2). In all insulin-
supplemented groups, 5% oxygen resulted in higher wet weight compared to the high (21%) 
oxygen partial pressure. The cell number per wet weight (Fig. 22C) decreased for all insulin-
receiving groups. 
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Glycosaminoglycans 
Primary chondrocytes 
The mass of GAG (Fig. 18D) increased after addition of growth factors. Between the different 
oxygen groups, the same trends as from wet weight could be found, i.e. the control 
(1.3/2.6 mg : 21%/5% O2) and the single growth factor-receiving groups showed higher 
values for 5% than for 21% oxygen (insulin 2.5µg/ml: 7.1/10.6mg; GDF-5 0.1µg/ml: 
5.3/7.5mg for 21%/5% O2). The combination of GDF-5 and insulin resulted in inverted 
results, i.e., a tendency to decreased GAG mass for the constructs cultivated under 5% oxygen 
partial pressure (GDF-5/insulin 0.1/2.5µg/ml: 17.0/13.8mg. for 21%/5% O2). In the GAG per 
cell (Fig. 18E) and GAG per wet weight (Fig. 18F) data differences could only be found 
between the control and the growth factor groups, but not within the different oxygen 
concentrations.  
Expanded chondrocytes 
Constructs supplemented solely with GDF-5 produced about equal mass of GAG (Fig. 22D), 
compared to the control (GDF-5 0.01µg/ml: 0.12mg; GDF-5 0.1µg/ml: 0.11mg; control: 
0.11mg; for 5% O2). All insulin-receiving groups resulted in significant increase of GAG 
mass (insulin 2.5µg/ml: 0.33mg), the combination of GDF-5/insulin even led to distinctly 
higher GAG content (GDF-5/insulin 0.01/2.5µg/ml: 0.26mg; GDF-5/insulin 0.1/2.5µg/ml: 
0.69mg; for 21% O2). The lower oxygen concentration of 5% resulted in higher GAG mass in 
the insulin groups (GDF-5/insulin 0.01/2.5µg/ml: 0.54mg; GDF-5/insulin 0.1/2.5µg/ml: 1.11 
mg; for 5% O2), compared to the respective groups receiving 21% oxygen. The higher GAG 
content of the insulin-receiving groups became also apparent in the GAG per cell (Fig. 22E) 
fraction.  
 





















































































































 Fig. 21: Data from primary chondrocyte constructs after 3 weeks of cultivation. All experiments were 
performed with four independent constructs per group. Group abbreviations: (I2.5): insulin 2.5µg/ml; (G0.01): 
GDF-5 0.01µg/ml; (G0.1): GDF-5 0.1µg/ml; (G0.01+I) or (G0.1+I): combination of insulin 2.5µg/ml and GDF-
5 0.01µg/ml or 0.1µg/ml, respectively.
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 Fig. 21: Data from primary chondrocyte constructs after 3 weeks of cultivation. All experiments were 
performed with four independent constructs per group. Group abbreviations: (I2.5): insulin 2.5µg/ml; (G0.01): 
GDF-5 0.01µg/ml; (G0.1): GDF-5 0.1µg/ml; (G0.01+I) or (G0.1+I): combination of insulin 2.5µg/ml and GDF-
5 0.01µg/ml or 0.1µg/ml, respectively. 
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 Fig. 22: Data from expanded (passage 2) chondrocyte constructs after 3 weeks of cultivation. All experiments 
were performed with four independent constructs per group. Group abbreviations: (I2.5): insulin 2.5µg/ml; 
(G0.01): GDF-5 0.01µg/ml; (G0.1): GDF-5 0.1µg/ml; (G0.01+I) or (G0.1+I): combination of insulin 2.5µg/ml 
and GDF-5 0.01µg/ml or 0.1µg/ml, respectively.
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 Fig. 22: Data from expanded (passage 2) chondrocyte constructs after 3 weeks of cultivation. All experiments 
were performed with four independent constructs per group. Group abbreviations: (I2.5): insulin 2.5µg/ml; 
(G0.01): GDF-5 0.01µg/ml; (G0.1): GDF-5 0.1µg/ml; (G0.01+I) or (G0.1+I): combination of insulin 2.5µg/ml 
and GDF-5 0.01µg/ml or 0.1µg/ml, respectively. 
 
 
An especially strong increase could be found for the GDF-5/insulin 0.1/2.5µg/ml combination 
(for 21% O2: GAG per cell: 183.2pg; GAG per wet weight: 1.89%); its GAG content 
increased distinctly compared to all other groups, especially when cultured under 5% oxygen 
(for 5% O2: GAG per cell: 210.4pg; GAG per wet weight: 2.55%). The differential oxygen-
dependent response with regard to GAG production was also confirmed by preliminary 
experiments (data not shown). 
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Collagen 
Primary chondrocytes 
The amount of produced collagen (Fig. 18G) increased with the application of insulin. 
Collagen mass ranged from 2.1mg (control, 21% O2) and 5.8mg (insulin 2.5µg/ml, 21% O2) 
to 11.0mg (GDF-5/insulin : 0.1/2.5µg/ml, 21% O2), which meant an 5.3-fold increase. Under 
lower oxygen partial pressure (5% O2) similar or only slightly higher results compared to 21% 
oxygen could be found for the control group (2.1mg vs. 3.4mg; 21% vs. 5% O2), insulin 
2.5µg/ml (5.8mg vs. 7.3mg; 21% vs. 5% O2) and the GDF-5 groups (0.01 and 0.1µg/ml). The 
groups receiving the growth factor combination with GDF-5 and insulin exhibited more 
obvious differences between the different oxygen conditions: The high oxygen groups 
resulted in significantly higher collagen production than the low oxygen groups (11.0mg vs. 
5.9mg, 21% vs. 5% O2 and GDF-5/insulin: 0.1/2.5µg/ml). Resulting collagen per cell (Fig. 
18H) and collagen per wet weight fraction (Fig. 18I) showed a tendency to lower values for 
all 5% oxygen groups compared to the respective 21% oxygen group, except for the controls. 
Further differentiations of the collagen composition were made by immunohistology and can 
be found below. 
Expanded chondrocytes 
The supplemented insulin led to increased collagen production in the scaffolds (insulin 
2.5µg/ml: 0.75mg for 21% O2, 0.71mg for 5% O2). For the groups receiving GDF-5 only, no 
significant differences in the mass of collagen (Fig. 22G) could be found. The combination of 
GDF-5/insulin (0.1/2.5µg/ml) led to the highest results in collagen production, as it increased 
up to 1.44mg and 1.30mg (for 21% and 5% O2, respectively. In the collagen per cell (Fig. 
22H) (e.g., insulin 2.5µg/ml: 301pg vs. 189pg for 21% vs. 5% O2) and collagen per wet 
weight (Fig. 22I) fraction (e.g., insulin 2.5µg/ml: 4.6% vs. 2.6% for 21% vs. 5% O2), all high 
oxygen groups (21% O2) resulted in higher collagen content, as compared to the respective 
low oxygen groups (5% O2). This finding was also confirmed by preliminary experiments 
(data not shown). 
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Histology 
Primary chondrocytes 
The GAG distribution within the primary chondrocyte constructs (Fig. 23) was further 
differentiated by safranin-O staining. Among the cross-sections from constructs of the high 
oxygen culture (Fig. 23A), a more saturated and continuous red staining of GAG could be 
found for increasing GDF-5 concentrations, which was further intensified by the 
supplementation of insulin, with a reduced blotchiness in the staining within the core of the 
scaffold.  
The cross-sections from the lower (5%) oxygen culture (Fig. 23B) exhibited a slightly lower 
saturation of the red staining and a tendency to a more scattered staining in the core of the 
scaffolds. 
Expanded chondrocytes 
The safranin-O staining of the expanded (passage 2) chondrocyte constructs (Fig. 24) showed 
smaller constructs with weaker staining, as compared to the constructs made from primary 
cells. By supplementation of growth factors strengthening of the staining was achieved. 
Especially the combination of GDF-5/insulin led to a saturated staining throughout the 
scaffold. For the combination with the high GDF-5 concentration (GDF-5/insulin 
0.1/2.5µg/ml) differences between 21% oxygen (Fig. 24A) and 5% oxygen (Fig. 24B) could 
be detected. The cross-sections from constructs cultured under 5% oxygen showed a more 
continuous and intense staining and lower blotchiness within the scaffold. 
As detected by the anti-collagen type II immunostaining (Fig. 25), the groups receiving the 
combination GDF-5/insulin were the only ones to produce collagen type II in the extracellular 
matrix, as an important marker for articular cartilage. Differences between the high oxygen 
(Fig. 25A) and the low oxygen (Fig. 25B) groups could not be found. 
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 Fig. 23: Safranin-O staining of primary chondrocyte constructs after 3 weeks of cultivation. Cross-sections in 
(A) were from constructs cultivated under 21% oxygen, in (B) from constructs cultivated under 5% oxygen. 
Group abbreviations: (I2.5): insulin 2.5µg/ml; (G0.01): GDF-5 0.01µg/ml; (G0.1): GDF-5 0.1µg/ml; (G0.01+I) 
or (G0.1+I): combination of insulin 2.5µg/ml and GDF-5 0.01µg/ml or 0.1µg/ml, respectively. 
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 Fig. 24: Safranin-O staining of expanded (passage 2) chondrocyte constructs after 3 weeks of cultivation. 
Cross-sections in (A) were from constructs cultivated under 21% oxygen, in (B) from constructs cultivated 
under 5% oxygen. Group abbreviations: (I2.5): insulin 2.5µg/ml; (G0.01): GDF-5 0.01µg/ml; (G0.1): GDF-5 
0.1µg/ml; (G0.01+I) or (G0.1+I): combination of insulin 2.5µg/ml and GDF-5 0.01µg/ml or 0.1µg/ml, 
respectively. 
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 Fig. 25: Anti-collagen type II immunohistochemical staining of passage 2 chondrocyte constructs after 3 
weeks of cultivation. Cross-sections in (A) were from constructs cultivated under 21% oxygen partial pressure, 
in (B) from constructs cultivated under 5% oxygen partial pressure. Group abbreviations: (I2.5): insulin 
2.5µg/ml; (G0.01): GDF-5 0.01µg/ml; (G0.1): GDF-5 0.1µg/ml; (G0.01+I) or (G0.1+I): combination of insulin 
2.5µg/ml and GDF-5 0.01µg/ml or 0.1µg/ml, respectively. 
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Discussion 
In the primary chondrocyte culture, constructs in the control group and the groups 
supplemented with a single growth factor showed increased wet weight under low oxygen 
(5%) partial pressure, as compared to 21% oxygen (1.4-fold increase for control, insulin 
2.5µg/ml and GDF-5 0.1µg/ml, 1.6-fold increase for GDF-5 0.01µg/ml), but not a change in 
extracellular matrix composition. The constructs supplemented with the growth factor 
combination GDF-5/insulin gave contrasting results, as the wet weight decreased for the 
lower oxygen culture conditions (1.2-fold decrease in wet weight for both GDF-5/insulin 
combinations, as compared to 21% oxygen); also the collagen fractions were reduced under 
5% oxygen, as compared to 21%. In histological analysis, under 5% oxygen the core of the 
GDF-5/insulin (0.1/2.5 µg/ml) constructs were found to be stained in a more scattered fashion 
as under 21% oxygen. The weaker extracellular matrix production under 5% oxygen might be 
an effect of the unfavorable nutrition situation in the core of the scaffold.  
 
Our findings are in agreement with the measurements of the oxygen pressure from Kellner et 
al. They measured the oxygen pressure in the center of the chondrocyte constructs, resulting 
in a oxygen pressure close to zero, and a strong oxygen gradient within the scaffold [111]. 
The relevance of these findings for natural cartilage were further discussed in a modeling 
analysis [126]. So it can be postulated, that the oxygen supply at 5% oxygen in this study may 
not be sufficient to support the metabolically highly active cartilage tissue or, as a second 
point, the increased size and volume of the scaffolds act as a diffusional barrier. In a cartilage 
pellet culture cells could cope with oxygen pressure below 0.1% for a minimum of 7 days 
[110]. After further culture for 21 days the low oxygen groups showed no significantly lower 
cell numbers, compared to their related high oxygen group. In the study presented here, also 
the cell fraction (cell number per weight) did not change with different oxygen partial 
pressure in any group. Thus, consistent with the report by Grimshaw and Mason [110], at low 
oxygen partial pressure the chondrocytes within the core of the scaffolds in our study might 
have reduced their metabolic activity resulting in the observed reduced ECM production.  
 
For the expanded chondrocytes, the low oxygen tension caused partially contrasting results 
compared to those for primary chondrocytes. At low oxygen partial pressure, all insulin-
receiving groups increased in wet weight (1.7-fold increase for insulin 2.5µg/ml, 1.4-fold for 
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GDF-5/insulin 0.01/2.5µg/ml) and cell number (1.5-fold increase for insulin 2.5µg/ml, 1.7-
fold for GDF-5/insulin 0.01/2.5µg/ml), as compared to culture of the respective groups under 
high oxygen. For the insulin-receiving constructs, also an increase in the GAG mass became 
detectable under 5% oxygen, as compared to 21% oxygen (1.2-fold increase for insulin 
2.5µg/ml, 2-fold for GDF-5/insulin 0.01/2.5µg/ml); a similar trend was observed for the GAG 
fractions per cell and per weight, respectively, suggesting a modulation of the tissue structure. 
In contrast, for almost all groups, low oxygen partial pressure led to decreasing collagen 
fractions per cell and weight, respectively, as compared to culture under high oxygen partial 
pressure. Especially in the collagen per cell (1.2-fold decrease for control, 1.6-fold for insulin 
2.5µg/ml, 1.8-fold for GDF-5/insulin 0.01/2.5µg/ml) and collagen per wet weight fraction 
(1.7-fold decrease for control, 1.8-fold for insulin 2.5µg/ml, 1.5-fold for GDF-5/insulin 
0.01/2.5µg/ml) this decrease became evident. With regard to the type of expressed collagen, 
expression of type II collagen did not seem to depend on the oxygen partial pressure, but on 
the usage of a suitable growth factor. Under both, 5% and 21% oxygen, the groups receiving 
the combination GDF-5/insulin were the only ones to distinctly express collagen type II.  
 
This result differs from literature, where dedifferentiated bovine chondrocytes in alginate 
beads deposited new collagen type II protein, but only when they were kept under 5% oxygen 
partial pressure, not under 21% oxygen [113, 114]. Similar results were found for 
dedifferentiated human chondrocytes embedded in alginate beads, which showed, under 5% 
oxygen partial pressure, increased expression of collagen II, Aggrecan and sox9, compared to 
the 20% oxygen groups [124]. The differences to the results of our study might predominantly 
be an effect of the different scales in cell construct size, as our scaffolds range from 4-7mm in 
diameter and are 2mm in height (for constructs from dedifferentiated chondrocytes); thus, 
they might be hard to compare with scaffolds cultivated in alginate beads with a diameter 
below 1mm. In our cell culture, more complex aspects of diffusion and nutrition appear to 
influence the development of the larger constructs.. 
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In general, the contrasting results of the conducted studies to date including the one presented 
here indicate that further research needs to be done with regard to the role of oxygen partial 
pressure within tissue-engineered constructs. Elucidating the influence of differential oxygen 
concentrations, also in distinct oxygen gradients within the scaffold [111], on cell spreading, 
cell density and extracellular matrix deposition within the scaffold, might lead to a tissue-
engineered cartilage material that possesses a layer composition similar or equal to natural 
cartilage. In parallel, further research in understanding ATP synthesis of the chondrocytes 
need to be done to explain the negative Pasteur effect and the source of non-oxygen related 
energy generation, as described elsewhere [116, 117]. Also we need a better understanding of 
the cellular response of chondrocytes to low oxygen, e.g., it has been suggested that it might 
be mediated by hypoxia inducible factor (HIF-1) [125].  
 
In our cell culture model, oxygen has a potential as a supporting tool which modulates the 
response to an applied growth factor. In general, it might be useful to improve cell culture 
conditions in 2-D or micro 3-D cell culture, as proven in alginate beads, and, in the future, 
might contribute to the engineering of small cartilage allografts. However, as of yet, specific 
standard oxygen conditions for cartilage engineering cannot be defined, as the tissue response, 
e.g., the extracellular matrix deposition has been too controversial in different studies.  
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Summary and Conclusions 
Articular cartilage is likely a major candidate to be successfully regenerated by tissue 
engineering methods; first commercial products have already reached the market. However, to 
fully regenerate articular cartilage tissue, further optimization appears mandatory with regard 
to the application of morphogens, the maintenance of chondrocyte phenotype by applied 
morphogens and improved culture conditions, and the composition of engineered cartilage 
constructs.  
Drug delivery systems in tissue engineering 
In this thesis, it was demonstrated that cartilage-effective proteins such as insulin can be 
released from cylindrical lipid matrices, preserving the bioactivity of incorporated and 
released proteins (chapter 3). In addition, it was demonstrated that the employed cartilage 
engineering in vitro assay facilitates the testing of controlled release devices with regard to 
their biological efficacy in a complex 3-D system without the need for the expense of 
laboratory animals (chapter 3).  
 
As a second controlled release device the suitability of solid lipid templated macroporous 
scaffolds as protein release system and at the same time as artificial cell carrier was proven 
(chapter 4). The embedded insulin was released from those smart scaffolds over an extended 
period of time under retention of its bioactivity facilitating the generation of cartilaginous 
constructs. 
Morphogens for cartilage tissue engineering 
In the area of morphogens, experiments with GDF-5 alone and in combination with insulin on 
expanded chondrocytes resulted in a clear shift of the cells towards the cartilaginous 
phenotype (chapter 5). Especially in combination with insulin, GDF-5 appeared to enable the 
redifferentiation of expanded chondrocytes and the concurrent generation of relevant 
cartilaginous constructs exhibiting substantial fractions of the extracellular matrix components 
glycosaminoglycans and collagen. With regard to the synergistic effects of GDF-5 and insulin 
observed, further research is required to elucidate the mechanism on the molecular level. The 
fact that GDF-5 was demonstrated to decisively modulate the response to another cartilage-
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effective protein contributes to the emerging picture of the role GDF-5 apparently plays in 
chondrogenesis and cartilage physiology.  
 
Further experiments were conducted investigating the effects of sexual steroid hormones on 
tissue engineered cartilage (chapter 6). In contrast to the previous chapters, the effects of 
testosterone, estrogen and dehydroepiandrosterone on extracellular matrix development and 
increase of wet weight of cartilaginous constructs were generally small and remained 
distinctly behind the anabolic efficacy of protein factors like insulin and GDF-5. From these 
preliminary experiments, no definite recommendation could be made for the application of 
steroid hormones in in-vitro cartilage engineering. Thus, further research needs to be 
conducted to get a more comprehensive view of the potential of steroid hormones in growing 
engineered tissues. 
Oxygen conditions in tissue engineering of cartilage 
Despite the oxygen partial pressure of 10% and lower in native articular cartilage, the 
majority of in vitro investigations including cartilage engineering approaches are conducted 
using an oxygen concentration of 21%. As a third aspect of this thesis, the effects of 
differential oxygen partial pressure (5% and 21% O2) on cartilaginous constructs were 
investigated (chapter 7). Taking together both the controversial results from many studies in 
the literature and the results obtained here, still specific standard oxygen conditions for 
cartilage engineering cannot be defined. Nevertheless, in our cell culture model it could be 
demonstrated that oxygen can be utilized as a supporting tool which modulates the response 
to an applied growth factor.  
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Abbrevations 
ANOVA analysis of variance 
BMP bone morphogenetic protein 
DAB diaminobenzidine 
DMEM  Dulbecco’s Modified Eagles Medium 
DNA desoxyribonucleinic acid 
ECM extracellular matrix 
ELISA enzyme-linked immunoassay 
FBS  fetale bovine serum 
GAG glycosaminoglycans 
GDF growth and differentiation factor 
HEPES N-2-hydroxyethylpiperazine N’-2-ethansulfonic acid 
HIF hypoxia inducible factor 
HPLC high performance liquid chromatography 
IGF insulin like growth factor 
MMP matrixmetalloproteinase 
MRI magnetic resonance imaging 
MW molecular weight 
PBS phosphate buffer saline 
PCR polymerase chain reaction 
PGA poly(glycolic acid) 
PLA poly(lactic acid) 
PLGA poly(lactic-co-glycolic acid) 
SD standard deviation 
SEM scanning electron microscopy 
TE tissue engineering 
TGF transforming growth factor 
UV ultraviolett light 
Ww wet weight 
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